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ABSTRACT
UPREGULATION OF ANGIOGENIC FACTORS BY PITUITARY TUMOR
TRANSFORMING GENE (PTTG) IN TUMORIGENESIS
MOHAMMAD TARIQ MALIK
May, 25 TH 2006

Pituitary tumor transforming gene (PTTG), also known as seCUrIng, is a novel
oncogene that is expressed at high levels in most of the tumors analyzed to date.
Overexpression of PTTG in mouse fibroblast (NIH 3T3) cells increases cell
proliferation, induces cellular transformation and promotes tumor formation in nude
mice. PTTG is a multi-domain and multifunction protein. Some functions of PTTG
include inhibition of pre-mature sister chromatid separation, activation of transcription
of c-myc oncogene, cell cycle regulation, and DNA repair. In some cancers such as
thyroid, pituitary, esophageal, and colorectal tumors, high PTTG expression correlates
with metastasis and poor prognosis. The PTTG gene encodes a protein of 203 amino
acids and is consists of six exons and four introns. The PTTG promoter is specifically
activated in tumors and is highly regulated by Sp 1 and NF -Y nuclear factors.
However, the precise mechanism by which PTTG mediates its tumorigenic function
remains unclear. To this end, we determined the effect of PTTG on tumor metastasis
and angiogenesis by determining its effect on secretion and expression of various
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angiogenic and metastatic factors including bFGF, VEGF, IL-8 and MMP-2. Using
RTIPCR, ELISA and zymography we showed a significant increase in expression and
secretion ofbFGF, VEGF, IL-8 and MMP-2 in HEK293 cells on transfection ofPTTG
eDNA. Down regulation of PTTG expression by siRNA and a genetically deleted
HCT116 (PTTG -1-) cell line showed significantly decrease in expression of MMP-2,
which led to decreased invasion and migration of HCT116 (PTTG-I-) cells as
compared to the HCTl16 wild type. Taken together, our results confirm that PTTG is
a potent tumorigenic gene that exerts its tumorigenic functions by increasing secretion
and expression of VEGF, bFGF, IL-8 and MMP-2 and MTI-MMP. In addition
expression of other angiogenic and adhesion molecules including beta-I, beta-3,
alpha-5 and alpha-V integrins was also modulated by PTTG in HEK293 cells.
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CHAPTER I
INTRODUCTION

Cancer is the second leading cause of death in the United States. An estimated
1.4 million new cases and 570 thousand deaths are expected in the year 2006 (1).
Overall worldwide, every year more than 11 million people are diagnosed with cancer,
leading to an estimated seven million deaths (2). Despite substantial advances made in
understanding tumorigenesis, complete knowledge of the underlying mechanisms that
lead to cancer initiation and progression remain unclear. Some of the factors that have
been reported to influence cancer development include, but are not limited to
environmental factors, genetic predisposition, and aging. Cancer development is a
complex and multi-step process that involves activation of proto-oncogenes, growth
factors, and their receptors, or deregulation of tumor suppressor genes leading to
abnormal cellular processes. Most importantly, the cancer cells exploit every
opportunity to deviate from the standard functions and restraints of normal cells.
Genetic aspect of cancer can be traced back more than 100 years

when von-

Hansenmann in 1890 and Boveri et al. in 1914 suggested aneuploidy, due to
chromosomal missegregation, as the fundamental basis of cancer (3-5). Since the
Boveri prediction it now seems that all solid tumor cells are not only aneuploid (6) but
they have acquired a number of mutations in oncogenes and tumor suppressor
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genes. Some of these genes include KRAS, TP53, APC, BRCAl, and RBI among
others. In addition cancer cell lines show a high level of chromosomal instability
(CIN) as a result of the loss or gain of whole chromosome or partial loss of
chromosomes during cell division (7).
The cause of chromosomal instability (CIN) is unknown, but one idea is
that it occurs due to a defect in the processes that control chromtid separation
during mitosis (8). Whether aneuploidy is a contributor, or just a reason for tumor
development, remains unanswered. It is known that a tumor originates from a
single altered cell, followed by sequential somatic, genetic or epigenetic changes
over a generation with increased aggressive subpopulation within the tumor mass
(9,10). Somatic evolution phenomena have been confirmed by numerous
molecular studies; it has been estimated that cells have to acquire five to seven
successive mutations to allow tumor growth, invasion and metastasis (11-13).
To identify the cause of tumorigenesis many cancer-causing genes have
been identified. Although they differ from tumor to tumor, loss or change in their
functions allows most cancers to acquire phenotypic differences. Hanahan and
Weinberg (14) described in detail phenotypic differences between healthy and
cancerous cells. The basic six phenotypic changes reported to occur at the cellular
level as essential hallmarks of cancer are: (a) unlimited mitosis; (b) evasion of
apoptosis; (c) resistance to growth-inhibition signals; (d) tissue invasion and
metastasis; (e) sustained angiogenesis; and (f) escape from the dependence on
external growth stimulation (14). Genetic instability is an additional factor which
accounts for the high incidence of mutations in cancer cells. Cancer susceptible

2

genes can be generally categorized into three classes: gatekeepers, caretakers and
landscapers (15,16).

Broadly speaking, gatekeeper genes are divided into two categories: (1)
oncogenes and (2) tumor suppressor genes (17,18). Mutations in any or both of
these types of genes operate similarly at the physiological level, and can exert
positive or negative regulatory properties on cell growth and proliferation.
Oncogenes are frequently activated by gain-of-function mutations, fusion with
other genes, amplification, increased expression as a result of increased promoter
activity, or protein stabilization (19,20). Hence these oncogenes genes play an
important role in diverse signaling pathways involved in various stages of human
cancer initiation, progression, angiogenesis and metastasis (17). Caretakers, or
stability genes, function to maintain the genomic integrity of the cell and regulate
DNA repair mechanisms, chromosome segregation and cell cycle check points
(18). Defects in caretaker genes lead to genetic instabilities that contribute to the
mutations in other genes, including oncogenes and suppressor genes that directly
affect cell proliferation and survival, thus promoting tumorigenesis (21-23).
Defects in landscaper genes do not directly affect cellular growth, but instead
generate an abnormal stromal environment that contributes to neoplastic
transformation of cells (17,23). Some examples of landscaper genes are
metalloproteinases (MMPs), uroplasminogen activator (uPA), tissue plasminogen
activator (tPA), fibroblast growth factor-2 (FGF-2) , and platelet-derived growth
factor (PDGF).

3

In summary, cancer is a complex and multistep genetic disease that
involves accumulation of genetic changes in somatic cells. These genetic changes
often involve activation of oncogenes and inactivation or loss of tumor suppressor
genes. However the mechanisms that initiate and promote tumorigenesis remain
unclear.

1.1

PITUITARY TUMOR TRANSFORMING GENE (PTTG)

To help understand the mechanisms of human tumorigenesis and to
identify the possibility for the existence of a common gene or signaling
mechanism, our laboratory cloned and characterized a novel oncogene: the
pituitary tumor transforming gene (PTTG), also known as mammalian securin,
from human testis (24) and ovarian tumors (25). Our initial studies were based on
the work of Pei et al (26), who used an mRNA differential display technique to
clone PTTG from a rat pituitary tumor. We and others showed that induction of
PTTG in mouse NIH3T3 fibroblast cells induces cell transformation in vitro and
in vivo (26-28). PTTG was found to be expressed in almost all tumors analyzed to

date, including tumors derived from the pituitary, adrenal, thyroid, liver, kidney,
endometrium, uterus, breast, testis, ovary, colon, as well as melanoma, leukemia
and various cell lines derived from these tumors (24,26,29-35). Expression of
PTTG is either very low or undetectable in normal tissues, except in the testis.
PTTG is reported to be a novel oncogene shown as a molecular signature gene,
whose expression in solids tumors is associated with metastasis and poor
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prognosis (36). Inactivation ofPTTG results in chromosomal loss with high levels
of chromosomal instability (37,38) and a defect in cell division (39).
Overexpression of PTTG causes tumor formation in nude mice (26) and tumor
cells are aneuploid (40,41). A strong correlation between aneuploidy, genomic
instability and overexpression of PTTG was shown by Kim et al (42) in follicular
thyroid cancer cells.

Zhang et al (35) showed a positive correlation between

PTTG levels and invasiveness of pituitary tumors. Similarly, Genkai et al (43)
showed a higher level of expression of PTTG in high grade tumor tissues from
patients with poor prognosis. PTTG has also been shown to be involved in
angiogenesis by inducing the expression and secretion of PGP (27) and VEGP
(44). In summary, PTTG is an important proto-oncogene, involved in many
cellular processes, and importantly, in tumorigenesis. Therefore, understanding
the mechanism by which PTTG induces tumorigenesis will help in identifYing
new signaling pathways and gene products that may help to understand complex
diseases and allow for the development of novel and more potent therapeutics
opportunities.

1.2

PRIMARY STRUCTURE OF PTTG

PTTG cDNA cloned from testis (24) and ovarian tumors (25) is composed
of 656 nucleotides, and encodes a protein of 202 amino acids, with an
approximate molecular weight of 24 kDa (25). However, PTTG migrates at 28 30 kDa on SDS-PAGE\ suggesting post-translational modifications (27,34,45,46).
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PTTG also migrates as a doublet, which is suggestive of phosphorylation status as
shown in (i

(26,47).

Sequence analysis of the PTTG protein showed no homology to other
proteins in the human genome (24,26). It is a multi-domain, natively unfolded
protein (48), and can be divided into two parts: the N-terminal regulatory domain
and C-terminal functional domain. The N-terminus contains a KEN box and Dbox surrounded by lysine residue, and serves as a target for anaphase promoting
complex (APC) for degradation (Figure

2)

(49). A mutation in the KEN box does

not prevent PTTG degradation, while a mutation in the D-box region partially
prevents degradation (45). However, a mutation in both KEN and D-boxes
completely abolishes PTTG degradation (50). The C-terminal functional domain
is more acidic and contains proline-rich motifs (PXXP), a casein kinase II (CKII)
phosphorylation site, and cyclic AMP and cyclic GMP protein kinase
phosphorylation sites (27,29,30,47). The proline-rich domain (PXXP) is known to
bind to various Src homology 3 (SH3) domain-containing proteins (51-53). The
SH3 binding domains mediate protein-protein interactions in signal transduction,
suggesting that PTTG may interact with other proteins that control its function,
regulation or trans-localization. However, no protein that interacts with these
sites has been identified.

6

Figure 1: PTTG is expressed in cell cycle dependent manner. A doublet for
phosphorylated PTTG protein is observed at M phase of cell cycle suggesting
potential for PTTG phosphorylation.
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Figure 1
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Figure 2: Major functional domains of PTTG, including DNA binding domain,
transactivation domain, and the critical proline rich (SH3) domains. Taken from
Bradshaw et al (54).
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However, the PXXP domains of PTTG have been reported to be involved in
bFGF and VEGF transactivation (55), as well as being involved in cell
transformation (27). It has been reported that serine 165 within the proline-rich
domain is the sole phosphorylation site for cyclin dependent kinase-2 (cdc2), (47)
and MAPK (56) is necessary during cell division to facilitate the function of
PTTG (47,55). Deletion or mutation of the proline-rich motifs abolishes the
transformation and tumorigenesis function of PTTG (27,55). Mutation of the
analogous murine serine at 162 position reduces PTTG mediated transactivation
by 75% (57). PTTG is mainly present in the cytoplasm with a partial nuclear
localization. Although PTTG lacks a nucloor localization sequence, the protein is
directed to the nucleus by interaction with PTTG binding factor (PBF) (47,56) or
phosphorylation by mitogen-activated protein kinase (MAPK) (56). It has also
been speculated that the small size of PTTG may help in the translocation into the
nucleus. In addition, PTTG has been shown to interact with p53 (58), Kuheterodimer (59), ribosomal protein S10, and a novel human homologue of
bacterial heat shock protein DnaJ; HSJ2 (60).

1.3

PTTG FAMILY OF GENES

The PTTG genes cloned from three species (rat, mouse and human) are
highly homologous. The human homologue of PTTG shares approximately

~80

% homology at the amino acid and nucleotide level, respectively, with the rat and
mouse genes. The PTTG gene was mapped to human chromosome 5q35.l, a
locus frequently associated with the reoccurrence of lung cancer and leukemia
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(Figure 3) (61,62). In adult human tissues, PTTG is most abundantly expressed in
testis, as well as in thymus, colon, small intestine, brain, placenta and pancreas
(24). Two additional members of the PTTG family have been identified (30).
After cloning of these members, PTTG was renamed as PTTG 1 and the other two
members as PTTG2 and PTTG3. All members of the family are transcribed from
different genes located on different chromosomes. PTTG 1 mapped to
chromosome 5q35.1 (61), PTTG2 to chromosome 4p12, and PTTG3 to
chromosome 8q22. PTTG 1 and PTTG3 encode the proteins of 202 amino acids.
Structurally they are same, but the function PTTG3 is not known (30,63). PTTG2
contains a deletion at nucleotide 541 which results in a frame shift and an early
stop codon, resulting in a truncated protein of 191 amino acids (Figure 4).
PTTGl, PTTG2 and PTTG3 are differentially expressed in normal and tumor
tissues (30). PTTG 1 has been most extensively studied. For simplicity, we will
refer to PTTG 1 as PTTG for the remainder of this dissertation.
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Figure 3: Genomic organization of the human PTTG. PTTG gene is located on
Chromosome 5 at 5q35.1. PTTG has six eKon and five introns and spans at least
10 kb. The cDNA is composed of 656 nucleotides and encodes a protein of 202
amino acids (30).

13

Figure 3

.....

...,

....'

....,

boo.

"lI1R

_.

" UTR AAAAAAAAAAAJAAA • •
Paty (AlllIil

Coding Retian

Start Codon

Stop Codon

Prolllle.fich Dnmal!l$

14

Figure 4: Amino acid sequence alignment of PTTG!, PTTG2 and PTTG3 gene
products. Clustal View (European Bioinformatics Institute).
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Figure 4

PTTG1 MATLIYVDKENGEPGTRVVAIIDGLKLGSGPSlKALDGRSQVSTPRFGKTFDAPPALPKAT
PTTG2 MATLIYVDRElGEPGTRVAAImVLKLESRPSlKALDGISQVLTPRFGKTYDAPSALPKAT
PTTG3 MATLIYVDKENEEPGILVATlIDGLRLGSGPSlKALDGRSQVSISCFGKTFDAPTSLPKAT

**********

***

*.:** *** * .******* ***

****:***.:*****

PTTG1 RKALGTVNRATBKSVKTKGPLKQKQPSFSAIOOfl'EKTVKAKSVPASDDAYPEIEKFFPF
PTTG2 RKALGTVNRATBKSVKTNGPBKQKQPSFSAKKMTEKTVKTKSSVPASDDAYPEIEKFFPF
PTTG3 RKALGTVNRATBKSVKTNGPLKQKQPSFSAKKMTEKTVKAKNSVPASDDGYPEIEKLFPF

*****************:** ******************:*.*******.******:***
PTTG1 NPLDFESFDLPEEHQIAHLPLSGVPLMILDEEBELEKLFQLGPPSPVRMPSPPHESNLLQ
PTTG2 NLLDFESFDLPEERQIAHLPLSGVPLMILDEEGELEKLFQLGPPSPVRMPSPPHECNLFA
PTTG3 NPLGFESFDLPEEHQIAHLPLSEVPLMILDEEBELEKLFQLGPPSPLKMPSPPHKSNLLQ

* *.*********:******** ********* *************:*******:.**:
PTTG1 SPSSILSTLDVELPPVCCDIDI
PTTG2 VSFKHSVDPGC----------PTTG3 SPLSILLTLDVELPPYCSDIDI
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1.4

BIOLOGICAL ROLES OF PTTG IN NORMAL CELLULAR

FUNCTIONS.

PTTG is a multi-functional protein that plays critical roles in cell cycle
progression, chromosomal stability and cell division (64,65). PTTG functions as
human securin to ensure that there is no premature separation of sister chromatids
by inhibiting separase, which is liberated from securin to degrade cohesin bound
to sister chromatids at anaphase (Figure 5) The level of PTTG expression is
increased rapidly in proliferating cells and is regulated in a cell cycle-dependent
manner (47,66). PTTG mRNA and protein-levels are low at the GIIS inter-phase,
and gradually increases during S phase with maximum expression at M phase.
PTTG undergoes complete degradation at anaphase by ubiquitinization and by the
recognization of the destruction box (D-box) consensus sequence of RxxLxxxxN
(67). The daughter cells after cell division express low levels of PTTG protein
(45). Overexpression of PTTG inhibits separation of sister chromatids, resulting
in gene translocations, truncations and unequal number of chromosomes in
daughter cells (aneuploidy) (41,66).

1.5

EXPRESSION

AND

BIOLOGICAL

ROLE

OF

PTTG

IN

TUMORIGENESIS.

PTTG is abundantly expressed only in testis where it is believed to be
necessary for normal spermatogenesis (24). Moderate expression is found in the
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Figure 5: PTTG expression is cell cycle dependent. The mRNA and protein
expression of PTTG are low at the G 1 / S interphase, gradually increases during S
phase and peaking at G2 / M phase. PTTG is degraded as the cells enter the
anaphase and daughter cells express low levels of PTTG protein.
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Figure 5
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thymus, colon, and small intestine, brain, and pancreas (27), and very low or
undetectable levels are found in the kidney, ovary, breast, liver and adrenal
(49,60). In contrast, high levels ofPTTG mRNA and protein are detected in most
tumors including tumors of the pituitary, adrenal, ovary, endometrium, liver,
colon, lung, stomach, breast, thyroid and testicles (24,25,33,35,68-70). In colon
cancers, expression of PTTG strongly correlates with the degree of angiogenesis
and metastasis (33). The pituitary tumor transforming gene (PTTG) has been
shown as a signature gene among eight other genes associated with highly
metastatic solid tumors, and its expression was associated with metastasis and
poor prognosis (36).

A relationship between the survival rate and level of

expression of PTTG in esophageal cancer has also been reported (71).
Overexpression of human PTTG in mouse NIH3T3 fibroblasts and human
embryonic kidney (HEK293) cells resulted in increased cell proliferation,
induction of cells to form foci in monolayer culture and promotion of tumor
formation in nude mice (24,26,27,72). These results clearly suggest that PTTG is
a human oncogene.

The most important candidates for downstream targets of PTTG function
are c-myc oncogene and basic fibroblast growth factor (bFGF). Induction of
PTTG results in increased cell proliferation through activation of c-myc (73),
suggesting direct transactivation of c-myc by PTTG. In recent studies, Bernal et
al. (58) reported interaction of the PTTG protein with the p53 protein thereby
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blocking the specific binding of p53 to DNA resulting

III

inhibition of its

transcriptional activity (Figure 6).

As mentioned earlier, PTTG possesses transactivation activity (29,56).
Transient transfection of a fusion construct containing the GAL4-DNA-binding
domain linked to the C-terminal region of PTTG which contains the multiple
glutamic acid and proline residues characteristic of transcription activation
domains trans activates a luciferase reporter gene (29). PTTG mutants defective in
transactivating activity are unable to transform mouse fibroblast NIH3T3 cells,
suggesting that transactivating activity is im.portant for the oncogenic functions of
PTTG. Importantly, PTTG interacts with the c-myc oncogene product. Induction
of PTTG results in increased cell proliferation through the activation of c-myc
(73) by binding to the c-myc promoter near the transcriptional initiation site.
Furthermore, inactivation of PTTG results in chromosomal loss with high levels
of chromosomal instability (37,38). PTTG knockout mice show high levels of
chromosomal instability and abnormal cell division (39). On the other hand, overexpression of PTTG promotes tumors in nude mice (26), and these tumors are
aneuploid (40,41). Zhang et al (35) have shown a positive correlation between
PTTG levels and the invasiveness of pituitary tumors.

Interesting effects of PTTG on cellular proliferation have been reported,
Pei et al have shown that overexpression of PTTG in NIH3T3 cells slows down
the rate of cell proliferation, which is in contrast to the function of an oncogene
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Figure 6: PTTG up-regulates p53 transcription and its own expression.
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(26). Data from our laboratory and others have since shown that PTTG
overexpression results in cell cycle arrest and apoptosis (40,66,74), and these
effects are mediated through bothp53 dependent and independent pathways.

PTTG overexpression also induces the expression of the Bax protein a
known target of p53 (74). However, in another study where inducible PTTG
constructs were used, there was an increase in cell proliferation due to increases in
c-myc and MEKI expression (73). Altogether it seems that both cell proliferation

and inhibition of cell proliferation may be a function of cellular PTTG levels.
When PTTG levels are modestly

increase~

cell proliferation is stimulated, while

the converse is seen when PTTG levels are high.

Data from our laboratory (Malik et al; unpublished data) and others (75)
have shown that media from PTTG over-expressing cells promotes angiogenesis.
Many growth factors including bFGF, EGF, TGF-a and IGF-I in turn increase
PTTG expression in human cultured cell lines (33,76,77). It is not clear how
these growth factors increase PTTG expression, but increases in either PTTG or
growth factors result in enhanced expression of both. There is a positive feedback
of PTTG and growth factors, suggesting that PTTG and growth factors play
important complimentary roles in tumorigenesis. Besides these growth and proangiogenic factors, other angiogenic genes such as an inhibitor of DNA binding 3
(lD3), insulin-like growth factor-I (lGF-I) (76), matrix metalloproteinase-2
(MMP-2) (Malik et al; unpublished data), interleukin-8 (lL-8) (72), interleukin 10
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(IL-10) and mothers against decapentaplegic, dorsophila, homolog of 1 (SMAD1) are expressed after overexpression of PTTG in thyroid cells (76,78,79).
Decreases in expression of anti-angiogenic genes including thrombospondin-1
(TSP1), endostatin (42), and tissue inhibitor of metalloproteinases 2 (TIMP2)
have been observed (Malik et al unpublished data)

1.6

PTTG GENE REGULATION

To aid in understanding the mechanisms that regulate the expression of the
the in tumors, the PTTG gene was cloned Kom a human genomic library (61,62).
The PTTG gene is composed of six exons and five introns and spans at least 10kb.
Analysis of the 5' flanking region of the PTTG gene revealed that there is no
TATA box sequence within 25-35 nucleotides upstream of the putative
transcriptional start site. However, a CAAT box sequence at -474 bp from the
transcriptional start site was identified (80). In addition, a number of
transcriptional binding sites were identified including API, AP2, PEA3, SPI,
IRE, CHR (cell cycle homology region), CDE (cell cycle-dependent element),
CRE, ERE and NF-Y (34,46,80) (Figure 7). Recently our laboratory identified
Sp1 and NF-Y DNA binding sites in the PTTG promoter sequence. Sp1 increases
the PTTG promoter activity using luciferase reporter assays (81), whereas in the
presence of DNA damaging agents, p53 suppresses the expression of PTTG in an
NF -Y dependent manner (82).
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Figure 7: PTTG gene 5' flankiRg sequence. Various transcriptional
regulatory sequences are highlighted. Inverted triangles represent translational
start codon ATG.
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It

has

been established that PTTG

expression correlates with

tumorigenesis; however, the signaling pathways that regulate expression and
tumorigenesis have not been defined. Tfelt-Hansan et al (77) reported regulation
of PTTG expression in human astrocytes cells by two promaglinant mitogens,
epithelial growth factor (EGF) and TGF-a. Data from our laboratory and others
have demonstrated that both insulin and IGF-I regulate the expression ofPTTG in
breast tumor cell lines (76,79). The effects of insulin and IGF-I were found to be
mediated through activation of the Akt pathway, a downstream signaling pathway
common for insulin and IGF-I (Figure 8). Therefore, it is possible that insulin and
IGF-I regulated pathways contribute to the-growth and proliferation of tumors by
activating oncogenic molecular targets such as PTTG. Taken together thses data
strongly suggests an important role of PTTG in cell proliferation and
tumorigenesis.
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Figure 8: IGF I Insulin and EGF regulate the expression ofPTTG through insulin
I IGF-I and EGF signaling pathway.
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1.7

ANIMAL AND CELL CULTURE MODELS
To understand the importance of PTTG in vivo, Melmed et al (83)

generated mice lacking PTTG (PTTG -1-) and showed that such animals exhibited
aberrant cell cycle progression, premature centromere division chromosomal
instability, as well as tissue specific phenotypes, such as testicular and splenic
hypoplasia and thymic hyperplasia (83). In their extended studies these
investigators showed that male mice lacking PTTG (PTTG-I-) in late adulthood
showed impaired proliferation of

~-cells

and developed type-I diabetes at their

later adult hood, suggesting the importance of PTTG in

~-cells

proliferation and

insulin production (64). The function of PTTG in tumorigenesis was
demonstrated by the PTTG(-I-)/Rb(+I-) animal that showed reduced pituitary cell
proliferation and pituitary tumors (84). On the other hand, Abbud et al (85);
generated transgenic animals driving the PTTG expression under the control of (J.GSU-promoter and showed that transgenic male mice develop pituitary adenomas
and prostate hyperplasia due to increase in luteinizing hormone (LH) secretion
(85). We developed tissue specific trans gene mice that expressed PTTG under the
control of murine inhibitory substance 2 receptor (MISIIR) gene promoter to
target ovarian surface epithelium. This transgenic animal developed cystic
glandular hyperplasia of endometrium, and generalized hypertrophy of the
myometrium. There were no visible ovarian tumors in these transgenic female
mice (Shahenda et aI, unpublished data). These studies clearly demonstrate that
PTTG playa critical role in cell proliferation and tumorigenesis.
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1.8

EFFECT OF DOWNREGULATION OF PTTG

As described earlier, overexpression of PTTG in mouse fibroblast cells
increases cell proliferation, induces cellular transformation, and promotes tumor
formation in nude mice (24,27). These results suggest that there may exist a
relationship between the level of PTTG and tumorigenesis. Based on these results
we and others hypothesized that down regulation of PTTG mRNA levels should
inhibits tumor cell proliferation and reverse the cancer phenotype. Use of small
interfering RNA (siRNA) technology (86), and adenovirus mediated siRNA (87)
or antisense oligodeoxynucleotides (anti-ONDs) (86,88) are well established
techniques to reduce the expression of a specific gene. To demonstrate the
possibility that down regulation of PTTG may reverse the cancer phenotype and
PTTG may serve as a molecular target for cancer treatment, Kakar and Malik (54)
showed that transfection of lung tumor cells with PTIG specific siRNA resulted
in a significant reduction in PIIG mRNA, and protein. Furthermore, these
transfected cells also demonstrated reduction of both colony formation on soft
agar and tumor formation in nude mice. siRNA effects are short-lived. Therefore,
to study the function of PITG and MMP-2 expression and secretion, we used a
human colorectal cancer cell line (HCTl16), in which both the copies of PTTG
gene are inactivated genetically by homologous recombination (PTTG -/HCTl16) cell (89). More details of this study are explained in chapter IV.
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In summary, cancer is the leading cause of death in the United States. It
has been established that tumorigenesis is a multistep process, involving
activation of proto-oncogenes, growth factors and their receptors and inactivation
of tumor suppressor genes. Abnormal expression of a gene in tumor cells can be
associated with several of characteristics that distinguish these cells from normal
cells. These characteristics includes altered cell differentiation, DNA repair, cellcell communication, cell matrix interaction, tumor invasion, migration,
metastasis, angiogenesis and apoptosis. Our lab cloned a potent oncogene
pituitary tumor transforming gene (PTTG) from human testis. The PTTG cDNA
is composed of 656 nucleotide and encodes a protein of 202 amino acid with no
homology to other known proteins. Over-expression of PTTG in mouse fibroblast
NIH3T3 cells resulted in increased cell proliferation and induced cellular
transformation. Furthermore, injection of PTTG stably transfected NIH3T3 cells
into nude mice resulted in tumor formation, suggesting a role for PTTG in
tumorigenesis. PTTG may induce its tumorigeneic function through increased
bFGF, VEGF, and IL-8 expression and secretion. With the exception of testis and
fetal liver, the levels of PTTG are either very low or undetectable in normal
tissue. The PTTG is expressed at high levels in almost all tumors including ovary,
kidney, pituitary, breast, uterus, liver and testis. There are two more members of
PTTG family, PTTG2 and PTTG3. All three members of PTTG family are
differentially expressed in normal and tumor tissue. PTTG 1 has been most
extensively studied. Down regulation of PTTG by siRNA results in loss of cell's
tumorigeneic function.
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1.9

HYPOTHESIS AND SPECIFIC AIMS

There is compelling evidence in the literature to suggest that PTTG is a
proto-oncogene overexpressed in most tumors and tumor-derived cell lines.
Overexpression of PTTG inhibits chromatid separation leading to genetic
instability and ultimately tumorigenesis (45). Studies have shown that transient
expression of PTTG in mouse fibroblast NIH3T3 cells increases the expression
and secretion of VEGF and bFGF, (27,90) potent mitogens in angiogenesis
(91,92). PTTG also possesses transactivation activity, which is related to its
transformation ability, suggesting a role in regulating the transcription of target
genes that can regulate its function (47,57). Taken together these results suggest
that PTTG is a multifunctional protein and mediates its functions through multiple
signaling pathways. All functional studies of the oncogenic properties of PTTG
have been performed using mouse fibroblast cells (NIH3T3) (29,35), an ideal cell
line for studying the behavior of oncogenes and tumor suppressor genes because
of its indefinite growth in culture, retention of contact inhibition, and ease of
transformation (93).

Due to biological differences between human and rodent

cells, however, care must be taken in extrapolating results obtained using rodent
cells to human cells. There are many examples in which overexpression of an
oncogene can induce transformation of primary rodent cells, but fails to induce
transformation in human counterpart. Therefore, it is important to test the
oncogenic abilities of PTTG in human cell line to establish its role in human
tumorigenesis.
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1.10 SPECIFIC AIMS

SPECIFIC AIM 1:

To determine the role of PTTG in human tumorigenesis using human
immortalized cell line.

RATIONALE
Overexpression of PTTG in mouse primary cells induces cellular
transformation and promotes tumor formation without the co-operation of other
genes. Data from our lab and others (24,27) have shown that over-expressing
PTTG in mouse NIH3T3 cells increased cell proliferation and cellular
transformation in vitro, and promoted tumor formation in vivo.

PTTG over-

expression is also known to induce expression ofbFGF and VEGF (90). Increased
expression of bFGF and VEGF has been reported in several human tumors and is
considered to be stimulating for angiogenesis (94). However, whether PTTG
transforms human cells has not been demonstrated. Major biological differences
between human cells and rodent cells make it difficult to extrapolate the results
from rodents to humans (95). There are a number of instances where overexpression of oncogene in rodent cells fails to transform human cells (96,97).
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SPECIFIC AIM: 2
To determine the role of PTTG in up-regulation and secretion of
metalloproteinases in tumor angiogenesis and metastasis.

RATIONALE

PTTG has been reported to increase levels of angiogenic and metastatic
factors including bFGF and VEGF (27,90). In limited studies of colorectal and
pituitary adenocarcinomas, a relationship between PTTG expression and
metastasis has been reported (33,68). However, the mechanism by which PTTG
regulates metastasis remains unclear. For a tumor to metastasize, many degrading
proteinases must be activated to facilitate movement of tumor cells from the
primary site to invade distance sites and metastasize. Matrix metalloproteinases
(MMPs) are known to play a key role in such processes by degrading the
extracellular matrix and controlling activities of growth factors, chemokines and
cytokines that favor tumor metastasis (98). We hypothesized that regulation of
tumor angiogenesis and metastasis is controled by PTTG by regulating the
expression and secretion of matrix metalloproteinases.
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SPECIFIC AIM: 3.
To determine if decreased PTTG expression in cancer cells reverses the
cancer phenotype and reduces angiogenesis and metastasis through down
regulation of metalloproteinases.

RATIONALE
PTTG is a potent oncogene that promotes tumor formation in nude mice.
PTTG has also been shown to regulate the

~xpression

of many growth factors and

cytokines induding bFGF, VEGF, and IL-8 (72). These factors are key regulators
of tumor angiogenesis and metastasis. PTTG increases the expression and
secretion of MMP-2. MMP-2 is known to be implicated in the aggressive and
metastatic tumor phenotypes with poor survival outcomes. If PTTG is essential in
regulating angiogenesis and metastasis, we perdict deletion of PTTG will reverse
the cancer phenotype remain unknown. In our study, we will deplete the
expression ofPTTG by using specific siRNA or will use HCTl16 (PTTG -1-) null
cell line where the PTTG gene is inactivated by homologous recombination, and
its counterpart wild type HCT116 (PTTG +1+) as a control to study the effect of
PTTG on MMP-2 expression and secretion.
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CHAPTER II
SECTION I
GROWTH FACTORS AND CYTOKINES

INTRODUCTION

Growth factors and cytokines are. small secreted molecules. That activates
signaling cascades in target cells by binding to specific cell specific surface receptors.
Two types of receptor are important: receptor tyrosine kinases and G-protein-coupled
receptors. The action of growth factors is mainly mediated through receptor tyrosine
kinases (RTK) while cytokines act through G-protein-coupled receptors (GPCR).
These mediators influence cell proliferation in a positive or negative manner by
inducing a series of intracellular signaling cascades that regulate diverse biological
responses. Cytoplasmic molecules that mediate these responses are called second
messengers. Among the intracellular signaling proteins are kinases, phosphates, GTPbinding proteins. The ultimate transmission of these signals to the nucleus effects the
expression of many genes involved in mitogenic and differentiation response.
Pathogenic expression of critical genes in response to constitutive expression of
growth factors and cytokines can contribute to altered cell growth associated with
malignancy (99). Almost all tumors can activate the angiogenic switch by changing
the balance of
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angiogenic inducers such as growth factors and cytokines required to sustain neovascularization. These growth factors include bFGF, VEGF, IL-8, IL-1O and
countervailing inhibitors such as thrombospondin-l (98,100,101).

Cancer development is a complex and multi-step process that involves
activation of oncogenes, growth factors, and their receptors, or deregulation of tumor
suppressor genes, leading to abnormal cellular processes. The growth and proliferation
of cells requires heterotypic mitogenic growth signaling, i.e. growth factors are
synthesized by one cell type in order to stimulate the proliferation of another cell type
(14). Instead, cancer cells acquire the ability to synthesize growth factors to which
they are responsive to, thus creating a positive feedback signaling loop. This autocrine
signaling obviates the dependence of cancer cell on growth factors from other cells
and provides growth signal autonomy. In this manner cancer cells modulate external
and internal signals that regulate their uncontrolled proliferation and evade apoptosis
(14,100). Furthermore, all mammalian cells are programmed for a limited number of
cell divisions cycles, which must be disrupted in cancer cells in order to expand to a
macroscopic size beyond 1 - 2 mm. Cancer cells, may continue to proliferate until
their oxygen and nutrient supply is limited by access to the vasculature. Thus,
angiogenesis is a crucial factor in the progression of tumor growth. During
angiogenesis, tumors activate an angiogenic switch by shifting the balance of gene
transcription towards angiogenesis inducers, such as growth factors and cytokines, and
countervailing angiogenesis inhibitors (98). Many tumors increase the expression of
vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and acidic and basic
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fibroblast growth factors (FGF 1 and 2), while expression of endogenous inhibitors
thrombospodin-l or p-interferon is decreased (78).

Basic fibroblast growth factor

(bFGF) and vascular endothelial growth factor (VEGF) (102,103) are strong mitogens
for endothelial cells and have been reported to play an essential roles in angiogenesis,
and stimulation of cell migration and metastasis (104-108). Interleukin-8 (IL-8)
belongs to a super-family of CXC chemokines, and is a multifunctional cytokine that
exhibits potent angiogenic and pro-inflammatory activities both in vitro and in vivo
(109).

Data from our laboratory (24,72) and others (27) have shown that overexpression of

PTTG cDNA in mouse NIH3T3 fibroblast cells increases the

expression of bFGF and induces cellular transformation and increased cell
proliferation. Further, stably transfected mouse NIH3T3 fibroblast cells constitutively
expressing PTTG injected into nude mice produce tumors. However, a role for PTTG
in transformation of human cells has not been demonstrated.

There are discrepancies between mouse and human carcinogenesis (95,110).
Despite similarities between mouse and humans, murine models of human
carcinogenesis are questionable due to differences in environmental conditions,
metabolic stability, and the robustness of the cellular regulatory network (111). Major
biological differences between human and rodent cells make it difficult to directly
extrapolate the results from mice to human (95). There are a number of instances in
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which over-expression of oncogenes transformed rodent cells but failed to transform
the same cells from humans (96,97).

To determine the role of PTTG in human tumorigenesis, we used the human
embryonic kidney cell line (HEK293) in our studies as a model. The cell line was
transformed by human adenovirus type 5 to prevent senescence (112). This cell has a
moderate tumorigenic potential and have been extensively used to study the oncogenic
potential of a number of genes (113-115). Mice xenografted with these cells do not
develop tumors, even three months after injection (115).
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SECTION II

Ectopic expression of PTTG/Securin promotes tumorigenesis in
human embryonic kidney cells.

2.2

SUMMARY

Pituitary tumor transforming gene (PTTG) encodes a protein that is primarily
involved in the regulation of sister chromatid separation during cell division. The
oncogenic potential of PTTG has been well characterized in the mouse, particularly
mouse fibroblast (NIH3T3) cells, where it induces cell proliferation, promotes tumor
formation and angiogenesis.

To determine if PTTG functions as an oncogene in

humans, we have characterized its effects on human embryonic kidney (HEK293)
cells. We found that introduction of human PTTG into HEK293 cells through
transfection with PTTG cDNA resulted in increased cell proliferation, anchorageindependent growth in soft agar, and formation of tumors after subcutaneous injection
of nu/nu mice.

Pathologic analysis revealed that these tumors were poorly

differentiated. Analyses of HEK293 cells transiently transfected with PTTG cDNA
and tumors developed after injection of HEK293 cells stably transfected with PTTG
cDNA indicated significantly higher levels of secretion and expression of bFGF,
VEGF and IL-8 compared to HEK293 cells transfected with pcDNA3.1 vector or
uninvolved tissues collected from the mice. Mutation of the proline-rich motifs at the
C-terminal region of PTTG abolished its oncogenic properties. Mice injected with this
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mutated PTTG either did not form tumors or formed very small tumors. These results
suggest that PTTG is a human oncogene that possesses the ability to transform human
without cooperation of other oncogenes in part through regulation of expression or
secretion ofbFGF, VEGF and IL-8.

2.2.1

INTRODUCTION

Pituitary tumor transforming gene (PTTG), a recently characterized oncogene,
was initially identified on analysis of a rat pituitary tumor (26); subsequently, a human
homologue ofPTTG was cloned by us and others (24,27,29). Three members (PTTG,
PTTG2 and PTTG3) of the PTTG family, which exhibit differential expression in
normal and tumor cells have been reported (30), although only PTTG has been studied
in detail.

PTTG is located on chromosome 5q33 (61), a locus associated with

recurrent lung cancer and myelogenous leukemias (62). Moreover, it has been shown
to be expressed highly in various tumors, and cell lines derived from such tumors,
including tumors of the pituitary, thyroid, colon, ovary, testicles and breast (25,33,6870). In normal tissues, its expression is low or undetectable except in testis (24,26).
Recent studies have indicated that elevated expression of PTTG in some tumors may
serve as a prognostic marker for tumor invasiveness and metastasis (36). A clue to its
function was gained from its structural similarity with the yeast securin, which led to
its identification as a human securin (45), and suggested that it may play a role in
regulation of sister chromatid separation. It appears, to have multiple effects in cells
including enhanced expression associated with an increase in the expression of the c-
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myc oncogene (73), an increase in the expression of p53 (40,74), an increase in the
secretion and expression of basic growth factor (bFGF) (75), and an increase in the
secretion and expression of vascular endothelial growth factor (VEGF) (75,90).

To date, evidence for the oncogenic function of PTTG has been obtained by
overexpression of PTTG in mouse fibroblast cells (NIH3T3) followed by assessment
of its ability to induce cellular transformation in vitro (colony formation in soft agar)
and tumor formation in nude mice (24,27).

Due to differences between human and

rodent cells, care must be taken in extrapolating results obtained using rodent cells to
human cells.

There are now several examples in which overexpression of an

oncogene induces transformation of primary rodent cells(96), the same strategy failed
to induce transformation of the same cell type derived from humans. Usually this
failure is attributable to the requirement for co-expression of another gene or
oncogenic cooperation of other genes (116-120).

Similarly, much of the evidence concerning the mechanisms by which PTTG
may affect the phenotype of the cell has been obtained using transfected NIH3T3
cells. It is known that the secretion of growth factors and cytokines by tumor cells,
and the cells that infiltrate and surround the tumor mass play an essential role in the
regulation of tumor growth and metastasis (121). Both bFGF and VEGF have been
implicated in tumorigenesis and the expression and secretion of these molecules has
been demonstrated on transfection of NIH3T3 cells with PTTG cDNA (75,90), but
this has not been confirmed with transfection of human cells. The effect of PTTG
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expression on another cytokine that is known to play a key role in tumorigenesis,
interleukin-8, (IL-8), have not yet been analyzed.

The purposes of this study were three-fold. First, to determine whether PTTG
can induce cellular transformation of normal human cells; second, to determine if
PTTG is sufficient to induce transformation; and, third, to characterize changes in
secretion and expression of key metastatic, angiogenic and chemokine factors (bFGF,
VEGF and IL-8).

For these studies, we selected the human embryonic kidney

(HEK293) cell line as our model. The expression of the SV40 large T antigen by
these cells prevents their senescence, but they do not exhibit tumorigenic
characteristics nor do they develop into tumors when xenografted into nude mice
(120,122).

2.2.3 MATERIAL AND METHODS
Generation of cell lines constitutively expressing PTTG:

The human embryonic kidney cell line (HEK293), which had been transfected
previously with SV40 large-T antigen, was purchased from ATCC (American Type
Culture Collection; Rockville, MD) and cultured according to the instructions
provided. The cells were transfected with pcDNA3.1 vector, pcDNA3.1-PTTG or
pcDNA3 .1-mPTTG to generate stable clones that constitutively express human wildtype PTTG or mutated PTTG (mPTTG) protein as described previously (24). The
mPTTG, which carries a double amino acid change within the SH3 binding domain of
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PTTG (p 163 to A 163 ,

p170

to A 170 and p172 to A 172, and

p

173

L 173 ), was generated by site-

directed mutagenesis using the Quick-change mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer's instructions. Mutation of these amino acids has
been reported to abrogate the tumorigenic function of PTTG and to block the secretion
and expression of bFGF in mouse NIH3T3 cells (27). The primers used for this sitedirected mutagenesis were 5' -GATGCTCTCCGCACTCTGGGAATCCAATCTG-3'
and 5'-TTCACAAGTTGAGGGGCGCCCAGCTGAAACAG-3'.

The transfected

cells were then selected in neomycin G418 (500 J..lg/ml) and the clones that expressed
high levels of PTTG protein or mPTTG protein were selected. One clone from
pcDNA3.l transfected cells (HEKpcDNA3.l) two clones from pcDNA3.l-PTTG
transfected cells (HEKPTTG-l and HEKPTTG-3) and two clones from pcDNA3.lmPTTG transfected cells (HEKmPTTG-2 and HEKmPTTG-4) were propagated into
cell lines.

Cell proliferation assay:

Cell proliferation was assayed using the CellTiter 96 non-radioactive cell
proliferation assay kit (Promega, Madison, WI) according to the manufacturer's
instructions and as described previously (24). Briefly, cells growing in log phase were
trypsinized and seeded in 96-well plates (5,000 cells/well in a final volume of 100 J..lI)
in replicates of 4 and incubated at 37 0 C in 5% CO2 and 95% air. After incubation for
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24 h, 48 h, 72 h or 96 h, 20 j.ll of dye solution from the kit was added to each well and
incubated at 37° C for an additional 2 h. The quantity of formazan product was
measured by its absorbance at 490 nm using a 96-well plate reader (Molecular
Devices, Sunnyvale, CA). Each experiment was repeated at least three times.

Soft agar colony formation (anchorage-independent cell growth) assay:

Anchorage-independent cell growth was determined by analyzing the
formation of colonies in soft agar. Cells (10 4) from each cell line were suspended in
0.3% agar in DMEM containing 10% fetal bovine serum and plated on solidified agar
(0.7%) in 35 mm dishes. After 14 days of culture, colonies formed were counted and
photographed as described previously (24).

In vivo tumor growth assay:

Cells growing in log phase were harvested by trypsinization and washed twice
with PBS. The cells were resuspended in PBS to a final concentration of 5x106/ml.
The cells (lx106 cells in 200 j.ll PBS/site) were injected subcutaneously (s.c.) into both
flanks of 5- to 6-week old female nu/nu mice (4 mice/group) (Charles River
Laboratory, Wilmington, MA). All procedures were carried out following the protocol
approved by The University of Louisville Institutional Animal Care and Use
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Committee. Four weeks after injection, the mice were sacrificed, and the tumors and
other tissues harvested. The skin and connective tissues were dissected from the
tumors, and the tumor volume was calculated from measurements of length x width x
height. The tissues were divided into two parts, one part being fixed in 10% buffered
formalin and the other stored in liquid nitrogen. For histopathologic analysis, 51lm
sections were cut from paraffin-embedded tissues, and mounted on slides. Sections
were stained with H&E (123), and processed for histopathologic evaluations.

Western blot analysis:

Cells growing in log phase were lysed in chilled lysis buffer [50 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM Na3V04, and 1 mM NaF] supplemented
with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals,
Indianapolis, IN). Equal amounts of protein extract (40llg) were resolved on 12%
SDS-PAGE gel, and transferred onto a nitrocellulose membrane (Amersham,
Piscataway, NJ). Blots were probed with PTTG antiserum at a dilution of 1: 1,500 as
described previously (124). Immunoreactive proteins were visualized using the
Enhanced Chemiluminescent Detection System (Amersham) according to the
instructions provided.

ELISA analysis ofbFGF, VEGF and IL-8

The levels of bFGF, VEGF and IL-8 in tissue culture supernatants and tissue
homogenates were measured using commercially available ELISA kits from BD
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Biosciences (Minneapolis, MN). To measure bFGF, VEGF and IL-8 in the culture
supernatants, HEK293 cells were transiently transfected with pcDNA3.1 or
pcDNA3.1-PTTG cDNA using Fugene6 as the transfectant reagent as described
previously (81). After 24 h of transfection, the medium was replaced with serum free
DMEM medium. Twenty-four hr later, the medium was collected and concentrated 5fold (1.0 ml to 200 Ill) using a speedVac system (Savant, Holbrook, NY). To measure
bFGF, VEGF and IL-8 in tumor and other tissues, tissues were homogenized in 50
mM Tris (pH 7.4), 0.25% Triton X-IOO, 5 mM EDTA and 0.1% NP40 supplemented
with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals,
Indianapolis, IN) using a polytron homogenizer. Homogenates were centrifuged to
remove particulate matter and then diluted with the diluent provided in the ELISA kit.
The concentration of bFGF, VEGF and IL-8 in a sample was determined by
interpolation from a standard curve. All measurements were normalized to protein
concentration and performed in triplicate.

Semi-quantitative reverse transcriptase/polymerase chain reaction (RTIPCR):

Total RNA from tumors and other tissues was purified using Trizol reagent
(Invitrogen, Carlsbad, CA) following the manufacturer's instructions. The RNA
pellets were resuspended in RNase-free water and the contaminating DNA was
removed from the preparations with DNase!. The yield of total RNA was measured
using a spectrophotometer and the quality was assessed by electrophoresis through a
1% agarose gel.

First strand cDNA was synthesized using the iScript™ cDNA
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synthesis kit (BioRad, Hercules, CA). PCR primers Cfable 1) were designed based on
the human PTTG, bFGF, VEGF and IL-8 cDNA sequences. The PCR conditions for
each gene are listed in Table 1.GAPDH amplification was used as an internal control.
Ten III from a total of 50111 PCR reaction mix was applied to a 2% agarose gel and
after electrophoresis; the gel was stained with ethidium bromide to visualize PCR
products. The densitometric values for the PCR-amplified products were quantified
using BioRad software and normalized against the GAPDH values.
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Table 1: Primer sequences and peR conditions for the amplification of PTTG, bFGF,
VEGF, IL-8 and GAPDH.
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Table 1

Sense Primer
Sequence

Antisense Primer
Sequence

PTTG

ATGGCTACTCTGAT
CTAT

AAAATCTATGTCAC
AGCAAAC

bFGF

TTCTTCCTGCGCAT
CCACCC

VEGF

GAATCATCACGAA
GTGGTGA

IL-8

ACCACCGGAAGGA
ACCATCT

GAPDH

TGATGACATCAAG
AAGGTGGT
GATGCTCTCCGCAC

MutatedTCTGGGAATCCAAT
PTTG
CTG

PCR Conditions

95°C 5 min, 95°C 30
s, 54°C 30 s, 72°C
30s. 28 cycles.
95°C 5 min, 95°C 30
CTCTTAGCAGACAT
s, 56°C 30 s, 72°C
TGGAAG
30s. 26 cycles.
95°C 5 min, 95°C 30
AACGCGAGTCTGTG
s, 56°C 30 s, 72°C
II II IG
30s. 28 cycles.
95°C 5 min, 95°C 30
GAATTCTCAGCCCT
s, 58°C 30 s, 72°C
CTTCAA
30s. 28 cycles.
95°C 5 min, 95°C 30
TCCTTGGAGGCCAT
s, 54°C 30 s, 72°C
GTGGGCC
30s. 26 cycles.
TTCACAAGTTGAGG 95°C 5 min, 95°C 30
s, 54°C 30 s, 72°C
GGCGCCCAGCTGA
30s. 35 cycles.
AACAG
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2.2.4 RESULTS

Generation of HEK293 cells stably expressing PTTG and mPTTG:

HEK293 cells were transfected with pcDNA3.l-PTTG, pcDNA3.l-mPTTG or
pcDNA3.1 vector. After G418 selection, 10 clones from each of pcDNA3.l,
pcDNA3.l-PTTG or pcDNA3.l-mPTTG transfected cells were picked, cultured, and
expanded.

The PTTG protein expression of these transfectants was detected by

western blot analysis using PTTG antiserum. Two representative clones from PTTG
transfected (named HEKPTTG-1 and HEKPTTG-3) and mPTTG transfected (named
HEKrnPTTG-2 and HEKrnPTTG-4), and one clone from pcDNA3.1vector (named
HEKpcDNA3.1) was selected for further studies. Selection of clones was based on the
level of expression of PTTG protein. (Figure 9) shows the protein expression of these
clones. Transfection of cells with the pcDNA3.1 vector resulted in expression of a
very low level ofPTTG protein. The clones of the pcDNA3.1-PTTG- and pcDNA3.lmPTTG-transfected cells that exhibited approximately equivalent levels of expression
of PTTG and mPTTG proteins were processed to establish stable cell lines.
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Figure 9: Western blot analysis of HEK293 cells transfected with pcDNA3.l,
pcDNA3.l-PTTG or pcDNA3.1-mPTTG. a: HEK pcDNA3.l, b: HEK PTTG clone 1,
c: HEK PTTG clone 3, d: HEK m-PTTG clone 2, and e: HEK m-PTTG clone 4.
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Stable transfection of PTTG induces cell proliferation and transformation of
HEK293 cells overexpressing PTTG.

Previously we have shown that over-expression of PTTG in mouse fibroblast
NIH3T3 cells results in an increase in cell proliferation (24). To determine if over
expression of PTTG in HEK293 cells produces similar effects, we estimated the
proliferation at 24, 48, 72 and 96 hours after plating of stably transfected HEK293
cells expressing high levels of PTTG or mPTTG protein. Both clones of PTTGtransfected cells (HEKPTTG-1 and HEKPTTG-3) exhibited significantly greater
proliferation than the cells transfected with vector only at all time points tested, and
the time course of proliferation was very similar in both clones, increasing by 30-40%
after 24 hours, 40-50% after 48 hours, 60-80% after 72 hours and 110-130% after 96
hours (Figure 10). Surprisingly, the proliferation of the cells expressing the mutated
PTTG was equivalent to that of the cells expressing the wild-type PTTG and was
significantly higher than that of the cells transfected with vector only.

These

experiments indicate that over expression of PTTG induces a significant proliferative
effect in HEK293 cells; however, at least under the conditions used, mutation of the
proline-rich motifs of PTTG did not affect this response.
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Figure 10: Cell proliferation of HEK293 cells stably transfected with pcDNA3.l,
PTTG 1 or mPTTG 1. 5 x 103 cells were plated / well. The results are expressed as
percent of control (HEK293 cells stably transfected with pcDNA3.l control vector).
Error bars ± SEM (n = 4) of three independent experiments. p<0.05
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Overexpression of PTTG induces cellular transformation.

Next, we assayed the effects of transfection with PTTG on the ability of the
HEK293 cells to form colonies in soft agar (anchorage-independent growth). As
shown in (Figure 11), over-expression of PTTG in HEK293 cells resulted in a higher
incidence of colony formation than that observed on transfection with the vector only.
The cells transfected with vector only formed few colonies and these were of small
size during 14 days of culture, whereas both the cell lines expressing wild type PTTG
formed a significantly higher number of colonies, which were of a large size. The
incidence of colony formation was 2% for HEKpcDNA3.l cell line but was 19% for
the HEKPTTG-l cell line and 30% for the HEKPTTG-3 cell line.

In this case,

mutation of the proline-rich motifs of PTTG resulted in a significant reduction in the
number of colonies formed with the incidence of colony formation for the
HEKmPTTG-2 and HEKmPTTG-4 cell lines being similar to the vector-only
transfected cells (HEKpcDNA3.l). These results suggest that over expression of
PTTG in HEK293 cells induces cellular transformation, and mutation of proline-rich
motifs does not effect the cell proliferation, but abrogates the cellular transformation
ability of PTTG.

I
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Figure 11: Colony formation of HEK293 cells stably transfected with pcDNA3.l,
pcDNA3.l-PTTGl or pcDNA3.1-m-PTTGl. a: HEK pcDNA3.1, b: HEK PTTGl, c:
HEK-PTTGl-3, d: HEK m-PTTGl-2 and e: HEK m-PTTGl-4.
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Figure 11
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PTTG induces tumor formation in nude mice injected with HEK293 cells stably
expressing PTTG protein.

To determine whether PTTG promotes tumor formation in nude mice, we
subcutaneously injected nude mice with HEK293 cells expressing PTTG or mPTTG.
Three out of four mice injected with the HEKPTTG-1 or HEKPTTG-3 cell lines
developed large tumors within four weeks of injection (Figure 12). Pathologic analysis
of the tumors revealed that they were poorly differentiated (Figure 13). Mice injected
with the HEKmPTTG-2 cell line also developed tumors, but the tumors were of a
small size. None of the mice injected with the other cell line-expressing mutant PTTG
(HEKmPTTG-4) or the vector-only cell line (HEKpcDNA3.1) developed tumors
within the time frame of this experiment. The tumor volumes, measured at the end of
experiment (six weeks after injection of cells), were 150-1320 mm3 for HEKPTTG-1,
72-1404 mm3 for HEKPTTG-3 and 8.8-12.6 mm3 for HEKmPTTG-2 (Table 2).
These results clearly demonstrate that PTTG gene is a potent oncogene.
Moreover, they demonstrate that PTTG possesses the ability to act alone to induce
transformation of human cells, and does not require the oncogenic cooperation of
other gene(s) to achieve its tumorigenic function.
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Figure 12: Tumor development in nulnu mice on injection of HEK293 cells stably
transfected with pcDNA3.1, pcDNA3.1 PTTG1 or pcDNA3.1 m-PTTG1 plasmids.
Each mouse was injected with 1 x 106 cells. Six weeks after injection, the mice were
photographed and sacrificed, tumor and other tissues were collected and tumor
volumes were measured. a: Mouse injected with HEK pcDNA3.1 cells, b: mouse
injected with HEK pcDNA3.1 PTTG1 cells, c: mouse injected with HEK pcDNA3.1
PTTGl-3 cells, and d: mouse injected with HEK pcDNA3.1 m-PTTGl-2. Arrows
indicate the tumors.
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Figure 12
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Figure 13: Histopathological analysis of the tumors excised from animals injected with
HEK293 expressing PTTG 1 or m-PTTG I. a: Normal HEK293 cells stained with
hematoxylin, b: tumor from animal injected with HEK pcDNA3.l PTTGI, c: tumor
from animal injected with HEK pcDNA3.l PTTGI-3.
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Figure 13
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Table 2: Tumor fonnation induced by PTTG 1 expressing HEK293 cells in nude mice.
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Table 2

Clone

Animals with
tumor

HEK pcDNA3.1

0/4

Tumor Volume
Ran2e
NA

HEKPTTGl-l

3/4

150-1320 mm

HEKPTTGl-3

3/4

72-1404 mm

HEKmPTTGl-4
HEKmPTTGl-2

2/4

8.8-12.6 mm3

0/4

NA
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3

3

PTTG stimulates expression and secretion of bFGF, VEGF and IL-S.

Local invasive growth is a key feature of primary malignant tumors. A
correlation between the levels of expression of PTTG with increased tumor
invasiveness and with the degree of malignancy has been demonstrated in pituitary
and colorectal tumors (33,125). The specific mechanisms by which PTTG facilitates
the invasive behaviors of tumor cells remain obscure. Recently Melmed et aI, (75,90)
have shown that transfection ofNIH3T3 cells with PTTG cDNA results in an increase
in secretion and expression of both bFGF and VEGF. A direct correlation between
high IL-8 expression and tumor metastases has been shown in a number of cancers
(109,126,127), and IL-8 also has been reported to possess mitogenic (128) and
angiogenic effects (129). We therefore measured the levels ofbFGF, VEGF and IL-8
in HEK293 cells transiently transfected with pcDNA3.1 or pcDNA3.1-PTTG cDNA
and in tumors developed on injection of nude mice with HEK293 cells that
constitutively express PTTG. As shown in (Figure 14A), the levels of bFGF, VEGF
and IL-8 were comparatively higher in conditioned medium of cells transfected with
pcDNA3.l-PTTG cDNA than from cells transfected with pcDNA3.1 vector only.
Cells transfected with pcDNA3.1-PTTG showed a 2-fold increase in bFGF, a 3.5-fold
increase in VEGF and a 2-fold increase in IL-8 levels compared to cells transfected
with pcDNA3.1 vector only. Measurement of the mRNA levels of these proteins by
RT/PCR showed significantly higher levels in cells transfected with pcDNA3.1-PTTG

cDNA

69

Figurel4: Overexpressing of PTTG in HEK293 cells induces secretion and expression
of bFGF, VEGF, IL-8. HEK293 cells were transiently transfected with pcDNA3.l or
pcDNA3.l-PTTGl eDNA. The culture media was removed, lyophilized and bFGF,
VEGF, and IL-8 secreted in culture medium were measured by ELISA. a: amount of
bFGF, VEGF and IL-8 in culture medium. Vector: cells transfected with pcDNA3.l
vector DNA; PTTGl: cells transfected with pcDNA3.l-PTTGl eDNA. B: Expression
of bFGF, VEGF and IL-8 mRNA in cells. Lane l: pcDNA3.1 transfected cells and
Lane 2: pcDNA3.l-PTTGl transfected cells. GAPDH was used as a loading control.
The data is representative of two independent experiments.
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PTTG1

Vector

PTTG1

compared to cells transfected with pcDNA3.l vector (Figure 14B). To determine if
over expression of PTTG results in increase in levels of bFGF, VEGF and IL-8 in
vivo, we measured the levels of bFGF, VEGF and IL-8 proteins in lysates from tumors
developed on injection of nude mice with HEK293 cells stably transfected with PTTG.
As shown in (Figure 15), the levels of bFGF, VEGF and IL-8 were significantly
higher in three out of four tumors compared to normal tissues (kidney, liver, lung and
heart) collected from the same animals. Since the size of the tumors that developed on
injection of cells expressing mutated PTTG (HEKmPTTG-2) were small, we were
unable to analyze the bFGF, VEGF and IL-8 levels in these tumors. Measurement of
mRNA for bFGF, VEGF and IL-8 revealed significantly higher levels of expression in
tumors compared to normal tissues and tumors developed on injection of
HEKmPTTG-2 cells (Figure 16). bFGF levels were found to be comparatively higher
in heart which is consistent with other investigators (130) Our results show that overexpression of PTTG in HEK293 cells resulted in an increased secretion and expression
ofbFGF, VEGF and IL-8 in vitro and in vivo, suggesting that increase in secretion and
expression of bFGF, VEGF and IL-8 by PTTG may be one mechanism by which
PTTG achieves its oncogenic function and increases tumor angiogenesis.
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Figure 15: Analysis of bFGF, VEGF and IL-8 expression by ELISA. Tumors and
other tissue were excised from the animals injected with HEK293 cells stably
transfected with PTTGI (clone 1 and 3) and homogenized. bFGF, VEGF and IL-8 in
the homogenates were analyzed by ELISA. Each analysis was performed in triplicate
tissue and was normalized to mg of protein. Error bars represent ± SEM of three
independent experiments.
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Figure 16: Analysis of expression of PTTG, bFGF, VEGF and IL-8 from tumors and
other tissues collected from mice injected subcutaneously with HEK293 cells stably
expressing PTTGI protein. a: RT-PCR analysis and , b: western blot analysis. Tl:
tumor 1, T2: tumor 2, M: HEK m-PTTGI-2, H: heart, K: kidney, Li: liver, Lu: Lung.
GAPDH and p-actin were used as control to examine equal loading. The gels are
representative of two independent experiments.
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2.2.4 DISCUSSION

The oncogenic function of PTTG was established by its overexpression in a
mouse fibroblast cell line (NIH 3T3) followed by assessment of its ability to induce
cellular transformation and tumor formation in nude mice (24,27). However, the
differences in biology between the rodent cells and human cells have brought the
validity of this model into question. There are a number of instances in which an
oncogene has been shown to induce transformation in rodent cells but failed to induce
transformation of the same types of cells obtained from humans. To test the ability of
PTTG to induce transformation in human cells, we selected the human embryonic
kidney- 293 (HEK293) cell line as our model. HEK293 cells have been transfected
with the large-T antigen and the expression of this molecule results in the cells
bypassing senescence and being immortalized. It has been demonstrated that
expression of large-T antigen does not convert these cells to the tumorigenic
phenotype nor do these cells develop tumors when injected into nude mice (120). Our
data clearly demonstrate that over-expression of PTTG in HEK293 results in an
increase in cell proliferation, induces cellular transformation invitro (increase in
anchorage-independent growth), and promotes tumor formation in nude mice. Cells
transfected with pcDNA3.1 vector did not form colonies in soft agar or develop into
tumors on implantation in nude mice, confirming that HEK293 cells do not possess a
tumorigenic phenotype. Thus, our results suggest that PTTG is a potent oncogene and
is capable of inducing tumorigenesis in human cells.
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A second issue that we were able to address using the HEK293 cell model is
the question of the ability of PTTG to induce transformation of normal human cells,
i.e., whether it acts alone or in cooperation with another oncogene to achieve its
tumorigenic function.

It has been reported that a single oncogene may not be

sufficient for induction of transformation, but requires co-expression, or oncogenic
cooperation, of another oncogeneses) to induce tumorigenesis in normal primary
human cells (96,116,118,119,131,132). Our data clearly show that PTTG is sufficient
to achieve its tumorigenic function without the cooperation of another gene.

PTTG contains several-proline rich motifs (PXXP); two of these that are
located in the C-terminal domain have been reported to be potential binding sites for
SH3-domians (133). In our study we confirm that mutation of these C-terminal
proline-rich motifs abrogates the tumorigenicity ofPTTG in human cells. Such loss of
tumorigenicity on mutation of PTTG could be due to a loss of expression.

Our

western blot analysis of the stable cell lines (HEKmPTT1-2 and HEKmPTTG-4) that
constitutively express mutated PTTG protein showed high levels of expression of
mPTTG protein, suggesting that the loss of tumorigenic function of mPTTG protein is
not due to loss of expression but due to the loss of its ability to induce cellular
transformation. These results are consistent with other investigators for rodent cells
(27) and confirm the importance of C-terminal proline-rich motifs to mediate the
oncogenic function of PTTG.
The molecular mechanisms by which PTTG achieves its tumorigenic function
remain unclear. PTTG has been reported to induce expression of the c-myc oncogene
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(56), bFGF (75) and VEGF (90). bFGF is a broad spectrum and pleiotropic mitogen
for growth and differentiation affecting various mammalian cells and organ systems
and a large number of cells lines (134). Besides stimulating wound healing, tissue
repair and hematopoiesis (135), bFGF induces cell migration and proliferation (91)
and acts as an agio genic factor that induces migration, proliferation and differentiation
of endothelial cells (136). In addition, it has been reported to modulate the invasion of
tumor cells through surrounding tissue to form new capillary cord structures by
regulating the activities of extracellular molecules including collagenase, proteinases
and integrins (136). Regulation of secretion and expression of bFGF by PTTG in NIH

3T3 cells has been shown (27). Consistent with these reports, our results demonstrate a
significant increase in secretion and expression of bFGF in HEK293 cells on transient
transfection with PTTG cDNA as well as in tumors developed by injection of stable
cell lines that constitutively express PTTG.

VEGF is a potent stimulant of the vascularization of tumors and is one of the
most specific markers of tumor vasculature observed to date (105,1 06). VEGF is a
multifunctional cytokine acting as a potent permeability agent, an endothelial cell
chemotactic agent, an endothelial cell survival factor and an endothelial cell
proliferation factor (137). The expression and secretion of VEGF has been shown to
be

a crucial rate-limiting step during tumor progression (108).

Our results

demonstrate a significant increase in secretion and expression of VEGF in HEK293
cells on transfection with PTTG and also from tumors excised from animals injected
with HEK293 cells that stably express PTTG.
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A direct correlation between high IL-S expression and metastases in melanoma
(109), ovarian cancer (126), prostrate cancer (127) and pancreatic cancer (13 S) has
been reported. To determine if overexpression of PTTG induces change in secretion
and expression of IL-S, we measured its levels in HEK293 cells on transfection with
PTTG cDNA and in tumors developed on injection of HEK293 cells transfected with
PTTG. Our results demonstrate for the first time that overexpression of PTTG induces
IL-S expression in vitro and also in tumors in vivo.

In summary, our results demonstrate that PTTG is a potent human oncogene
and has the ability to induce cellular transformation of human cells. Overexpression of
PTTG in HEK293 cells leads to an increase in the secretion and expression of bFGF,
VEGF and IL-S. Mutation of C-terminal proline-rich motifs abrogates the oncogenic
function of PTTG. To our knowledge, this is the first study demonstrating the
importance of PTTG in human tumorigenesis.

so

CHAPTER III
SECTION I
MATRIX METALLOPROTEINASES

INTRODUCTION

Metalloproteinases are a multigene family of metal-containing proteases that
share common structural and functional characteristics. All of the family members
sequenced to date have at least three common domains: (i) a prodomain which
contains a conserved cysteine residue that is lost on activation; (ii) a catalytic domain
which contains a conserved metal-binding site and (iii) a highly conserved zincbinding active site (Figure 17) (139). There are at least 24 members of the MMP
family, and that can be subdivided according to their substrate specificity. Regulation
of MMPs occurs at three different levels: alteration of gene expression, activation of
latent zymogens, and inhibition by tissue inhibitors of metalloproteinases (TIMP).
Among the members of the MMP family, gelatinases (MMP-2 and MMP-9) are the
most common metalloproteinases associated with tumor metastasis and angiogenesis.
Overexpression of MMP-2 has been correlated to an invasive phenotype in several
cancer types and is often predictive of poor survival (140). MMP-2 knockout mice
display lowered lung colonization following intravenous administration of cancer
cells, and reduced tumor angiogenesis resulting in
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Figure 17: Major functional domains of Matrix Metalloproteinases-2 (MMP-2).
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reduced tumor growth (141). Moreover, MMP-2 has been shown to be a prognostic
marker in ovarian cancer, lung cancer, and gastric cancer (142-144). MMP-2 is also
known to be involved in tumor angiogenesis through degradation of extracellular
matrix (ECM), which can result in tumor cells, and endothelial cell migration due to
loss of cell-matrix and cell-cell contacts (145). MMP-2 is also capable of releasing
growth factors that are from ECM, cleaving certain growth factor receptors and
activating growth factors, excreted as pre-pro-enzymes, such as transforming growth
factors (TGFa,

TGF~),

macrophage-colony stimulating factor (M-CSF), insulin like

growth factor (IGF), and fibroblast growth factor receptor (FGFR) (146-148).
However, as the MMP-2 activity may not always lead to angiogenesis and metastasis,
the mechanisms by which metalloproteinases are regulated remain unclear.
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SECTION II

Regulation of Angiogenesis and Invasion by human Pituitary tumor transforming
gene (hPTTG) through increased the expression and secretion of Matrix

Metalloproteinase-2.

INTRODUCTION:

Primary tumor growth is restricted due to a limited supply of oxygen, nutrients,
and growth factors. Tumor progression and invasion to distant organs depends on
tumor angiogenesis. To achieve angiogenesis various factors including transforming
genes and growth factors turn on to enable tumor progression (44). Once angiogenesis
is initiated, the tumors expand exponentially and invade to local and distance tissues.
From a patient survival perspective, understanding the mechanisms of angiogenesis
and development of new therapeutics to inhibit angiogenesis is a critical step leading
to inhibition of tumor growth and metastasis (98,99).

Many oncogenes have been reported to play important role in tumor
angiogenesis. Recently, a novel oncogene, pituitary tumor transforming gene (PTTG),
also known as securin, has been reported to playa vital function in tumor angiogenesis
(90). Using an mRNA differential technique, PTTG was originally cloned from rat a
pituitary tumor (26), followed by cloning homologue from humans (4-6). The
predominant cellular location of the PTTG protein is the cytoplasm, although it is
partially localized in the nucleus

(66). Nuclear translocation of PTTG can be

facilitated by either interaction with PTTG binding factor (PBF) (149), or by
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interaction with the mitogen-activating protein (MAP) kinase cascade (56). The level
of PTTG expression is increased in rapidly proliferating cells and is regulated in a cell
cycle-dependent manner (45). PTTG mRNA and protein expression are low at the
G liS interphase, gradually increase during the S phase, and peak at the G2/M phase
(45). As the cells enter anaphase, PTTG is degraded and daughter cells express very
low amounts ofPTTG. The degradation ofPTTG most likely occurs via ubiquitination
since PTTG contains a D box which is required for such proteolysis.

Numerous studies have demonstrated that human PTTG displays a distinct
pattern of expression. In normal tissues, PTTG expression is restricted, with high
levels in testis, and low levels in the thymus, colon, and small intestine (24,27). In
contrast, PTTG is highly expressed in a variety of human primary tumors as well as
tumor cell lines including carcinomas of the ovary, lung, testis, kidney, colon, thyroid,
pituitary, liver, adrenal, breast, prostate, melanoma, leukemia, and lymphoma
(24,25,29,33,36,47,66,80,150-153), suggesting that PTTG may be involved in
tumorigenesis. Furthermore, the expression level of PTTG correlate with increased
tumor invasiveness in human pituitary tumors with hormone overproduction (151),
and with the degree of malignancy, pathogenesis and/or progression of colorectal and
thyroid tumors (33,151,154). PTTG has been identified as one of eight signature genes
associated with tumor metastasis and up-regulated in human primary solid tumors
(36). A relationship between the survival rate and level of expression of PTTG in
esophageal cancer has been reported (71).
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We and others have shown that overexpression of human PTTG in mouse
fibroblasts (NIH3T3) and human embryonic kidney (HEK293) cells results in
increased cell proliferation, induction of cellular transformation in vitro and formation
of tumors in nude mice (24,27). Currently, the precise mechanism by which PTTG
causes cell transformation remains unclear. Data from our laboratory and others
suggest that PTTG may act through basic growth factor (bFGF) (24,155), vascular
endothelial growth factor (VEGF) (72,90), and/or interleukin-8 (IL-8) (72). Additional
mechanisms by which PTTG may induce its oncogenic function are indicated by
findings that implicate it in sister chromatid separation during cell division (45).
PTTG, by virtue of its function as human securin, ensures that there is no premature
separation of sister chromatids. Mice that lack PTTG show aberrant cell cycle
progression, premature centromere division, and problems with chromosomal stability,
as well as tissue specific phenotypes, such as testicular and splenic hypoplasia and
thymic hyperplasia (83). In addition, PTTG null mice exhibit impaired proliferation
of pancreatic beta cells and developed type I diabetes during late adulthood (64,83).
Furthermore, animal deficient in PTTG (-/-) demonstrat inhibition of tumor
development compared to Rb (+/-) induced tumors (84). On the other hand, transgenic
animals that express PTTG under the control of the aGSU promoter developed an
enlarged pituitary and hyperplasia of prostate (85). Taken together, these data strongly
suggest an important role of PTTG in cell proliferation and tumorigenesis and suggest
mechanisms that may contribute to these effects.
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Local invasive growth is a key feature of primary malignant tumors. A
correlation between the level of expression of PTTG with increased tumor
invasiveness and degree of malignancy in pituitary and colorectoral tumors has been
reported (33). However, the specific mechanisms facilitating the invasive behavior of
cancers remain obscure. Interactions between cancer cells and surrounding normal
cells and the extra-cellular matrix (ECM) are thought to be key event in tumor cell
invasion (140,146). To invade and spread through the surrounding normal tissue,
tumor cells must degrade multiple elements of the ECM, including fibronectin,
laminin, and type IV collagen (139,156). Several metalloproteinases (MMPs) are
required for the degradation of the ECM, and these are classified according to their
substrate specificity. MMP-2 and MMP-9 are the most common MMPs in tumors, and
the elevated levels have been reported in various cancers (139,157,158). In the present
study, we show that overexpression of PTTG in HEK293 cells results in up-regulation
of the secretion and expression of MMP-2, but not MMP-9, leading to increased cell
migration and invasion. These data suggest an important role for PTTG in tumor cell
migration and invasion.

3.2.2 MATERIAL AND METHODS
Material

Human embryonic kidney cells (HEK293) and Human umbilical vem
endothelial cells (HUVEC) were obtained form American Type Culture Collection
(ATCC, Manassa, VA) and maintained at 3JOC in a humidified atmosphere of 5%
CO 2 .

HEK293 cells were cultured in DMEM (GIBCO) supplemented with
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penicillin/streptomycin (100 IU/ml and 1OO~g/ml) (GIBCO) and 10% FCS (Hyclone,
Atlanta GA.). HUVEC cells were cultured in ECM medium (Clonetics, US)
supplemented with Bullet Kit (EGM-2, Clonetics, US). Cells passages were performed
routinely. The MMP-2 blocking antibody (MMP2BA) was obtained from Chemicon
USA. Porcine gelatin and clostridium collagenases were from Sigma Chemical Co.
(St. Louis, MO). DQ Collagen fluroescein conjugate was purchased from Molecular
Probes (Carlsbad, CA ).

GE Array Analysis of human extracellular matrix and adhesion molecules

The expression profile of extracellular matrix & adhesion molecules genes
were analyzed using the non-radioactive SuperArray GEArray Q series human gene
array (HS-OI0 SuperArray Bioscience Corp., Frederick, MD). This array membrane is
composed of 96 extracellular matrix & adhesion molecules genes, a plasmid pUC 18
negative control, and four housekeeping genes including glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), cyclophilin A, ribosomal protein L13a, and

~-actin.

Radioactive [a- 32P]dCTP labeled cDNA probes were prepared from 1 ~g of RNA
from pcDNA3.l and pcDNA-PTTG transfected HEK293 cells each, denatured and
hybridized to extracellular matrix & adhesion molecules gene-specific cDNA
fragments spotted on the membranes. After pre-hybridization with GEAhyb
Hybridization Solution (SuperArray) of denatured salmon sperm DNA (Invitrogen).
The array membrane was hybridized with denatured cDNA (labeled with a}2 P -dCTP)

probes overnight at 6QoC. After washiu% of the membrane twice with 2 x sse, 1%
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SDS and twice with 0.1

x

SSC, 0.5% SDS for 15 min at 55°C, the membranes were

exposed to x-ray film at _80°C for 24-48 h. The results were analyzed with ScanAlyzer
and GEArray Analyzer program. The relative expression levels of different genes
were estimated by comparing its signal intensity with that of internal control

~-actin.

ELISA for MMP-2 and MMP-9:

The levels of MMP-2 and MMP-9 in tissue culture supernatants were
measured using commercially available ELISA kits from BD Biosciences
(Minneapolis, MN). To measure MMP-2 and MMP-9 in the culture supernatants,
HEK293 cells were transiently transfected with pcDNA3.1 or pcDNA3.1-PTTG
cDNA using Fugene6 as the transfectant reagent as described previously (81). After 24
h oftransfection, the medium was replaced with serum free DMEM medium. Twentyfour hr later, the medium was collected and concentrated 5-fold (1.0 ml to 200 ).ll)
using a speedVac system (Savant, Holbrook, NY). The concentration of MMP-2 and
MMP-9 in a sample was determined by interpolation from a standard curve. All
measurements were normalized to protein concentration and performed in triplicate.

Transfection and collection of conditioned media:

For transient transfection, HEK293 cells were

seeded into six well plates

approximately 24 h prior to transfection,. Cells were transfected in serum-free medium
using l).lg of plasmid DNA and 3).l1 of transfectin (BioRad) according to the
manufacture's instructions. After 18 hr of transfection, medium was changed to
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serum-free medium (DMEM GIBCO) ± MMP-2 blocking antibody 2

~glml.

After 48

hr, conditioned medium (CM) were collected, centrifuged and stored at -80°C for

future use. Tissue lysates and stable clones of HEK293 cells transfected with
pcDNA3.1 or pcDNA-PTTG were generated as describe previously (72).

Matrix Metalloproteinases-2 (MMP-2) expression and secretion:
Zymograpby

Secretion and activity of MMP-2 in conditioned medium collected from cells
transfected with pcDNA3.1 or pcDNA-PTTG cDNA was used to perform gelatin
zymography analysis as described by Heussen et.al (159,160). Briefly conditioned
medium with or without MMP-2 blocking antibody (1: 1000) was collected and one ml
of medium was lyophilized and reconstituted with 100
determined by the Bradford method (161) and 20

~g

~l

of water. Protein was

of protein was loaded on

polyacrlyamide gels containing 0.1 % gelatin Sigma Co. (St. Louis, MO).
Electrophoresis was performed under non-reducing conditions at 20 rnA for 3 hr at
room temperature. The gel was washed twice for 30 min each in 2.5% Triton X-I00 to
remove SDS, incubated in substrate buffer (50 mM Tris-HCl, 5mM CaCh, 0.01%
NaN3 , pH 7.6) for 24 h at 37°C. Gels was stained with 0.5% Coomassie brilliant blue
G-250 (Pierce Rockford, IL) for 30 min at room temperature, and destained in the
de staining buffer (30% ethanol, 10% acetic acid, deionized water). The presence of
metalloproteinases (MMP-2) was indicated by an unstained proteolytic zone of
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substrate. The gel was scanned using NIH image software, and data are presented as
fold change relative to control i.e, pcDNA transfected conditioned medium.

Detection of collagenase activity in conditioned medium and tissue sections.

Collagenase activity in conditioned medium (CM)

Twenty III of collagen fluorescent substrate reconstituted in PBS was mixed
with 80 III of reaction buffer (0.5 M Tris-HCI, 1.5 M NaCl, 50 mM CaCh, 2 mM
NaN3, pH 7.6) and added to the fluorescent reader plate. Twenty III of conditioned
medium treated with or without MMP-2 blocking antibody was added to each well.
Clostridium collagenase, serially diluted was used as a positive control and 100 III of
reaction buffer was used as a negative control. The plate was incubated at room
temperature for 1 h. After incubation, the fluorescent intensity of the digested product
from DQ collagen was measured at excitation 495 nm and emission at 515 nm in the
fluorescent microplate reader. The fold change was calculated by dividing the mean of
fluorescence values of conditioned media collected from pcDNA transfected by the
mean value of fluorescence of conditioned media collected from pcDNA-PTTG
transfected with or without MMP-2 blocking antibody.

Collagenase activity in tumor tissue.

Collagenase activity was determined in tumor tissues extracted from nulnu
mice as describe previously (72). Briefly, DQ collagen substrate (lmg/ml) was mixed
with reaction buffer (0.5 M Tris-HCI, 1.5 M NaCl, 50 mM CaCh, 2 mM NaN3, pH
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7.6) containing 0.8% low melting agarose (Invitrogen) at a ratio of 1: 1 as described by
Peter et al (162). After melting the agarose mixture at 60°C, the mixture was applied
on the frozen tissue section on glass slides and allowed to solidify at room
temperature. Slides were incubated in a humidified chamber with a few drops of
reaction buffer on each slide for 5-7 days. Assessment of degradation of substrate was
examined with an Olympus IX50 fluorescent microscope, and photographed with a
KODAK DC290 digital camera.

Western blot analysis

Cells were lysed with lysis buffer (20mM Tris HCI pH7.5, 1 mM EDTA, 0.1%
Nonidet P-40, 1 mM PMSF, and Il!g/ml each of pepstatin, leupeptin and aprotinin)
and subjected to SDS-PAGE. The proteins were blotted onto nitrocellulose
membranes as described previously (124). PTTG protein was detected by using
polyclonal antiserum (1: 1500) to protein and HRP-conjugated secondary anti-rabbit
antibody (1 :5000), by the enhanced chemiluminescent substrate (ECL, Amersham).

Immunohistochemistry analysis

HEK293

cells

were

transiently

transfected

with

pcDNA3.l

or

pcDNA3.1 +PTTG vector in chamber slides (Fisher Scientific, Springfield, NJ). After
24 h of transfection, cells were fixed using 4% freshly prepared paraformaledehyde for
8 min and then permeabilized by treating with 0.1 % Nonidet P-40 for 5 min. Cells
were pretreated with 5% normal goat serum for 60 min to block nonspecific binding
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sites. The tissue was washed with PBS, incubated with anti-PTTG antiserum as
described (124), and MMP-2 monoclonal antibody(R&D) diluted at (1 :1500). Control
samples were incubated with preimune serum. After several rinses with PBS buffer,
the sections were incubated for 45 min with Texas Red conjugated anti-rabbit
secondary antibody and Texas green conjugated anti-mouse secondary antibody
(1:100) obtained from Jackson Immuno Research Laboratories (West Grove, PA).
Cells were analyzed using a fluorescent microscope (Olympus X50).

Reverse transcription-polymerase chain reaction (RT -peR)

Total RNA was isolated from transfected HEK293 cells in log phase and tumor
tissues using Trizol reagent (Gibco-BRL) as described previously (25). In brief,
samples were homogenized in 5 ml of Trizol reagent, after vortexing for 2 min, 1 ml
of homogenate was distributed in five 1.5 ml Eppendroff tubes and kept at room
temperature for 5 min, 1/5 volume of chloroform was added to each sample followed
by vigorous mixing and incubation for 2-3 min. The aqueous phase was removed after
centrifugation at 15,000 rpm and precipitated with isopropanol. The RNA was washed
once with 70% ethanol. After air-drying, the RNA was resuspended in RNase free
water. Total RNA concentration was determined spectrophotometrically at 260 nm.
Using iScript RT-PCR kit (Bio-Rad), first strand cDNA was synthesized and
subsequently used for PCR amplification using the specific primers for MMP-2, MTIMMP, PTTG, and GAPDH (72,163) (Table 3) using Taq polymerase (Takra Co.).
PCR conditions were 95°C for 5 min, 95°C for 1 min, 54°C for 30 sec and
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noc for 30

sec for 30 cycles with a final extension for 5 min at 72°C. Ten

~l

PCR product from

each sample was subjected to electrophoresis on a 1.5% agarose gel.

In-vitro invasion assay

PTTG stably transfected HEK293 cells were used for invasion and migration
assays. Boyden chamber matrigel coated wells (BD BioCoat Invasion System) were
used according to the manufactuer's instructions. HEK293 cells were dislodged nonenzymatically (TryplE, Invitrogen, IL) and resuspended in DMEM serum-free culture
medium, with or without MMP-2 blocking antibody at 2xl0 5 cells/ml and 0.25 ml of
cell suspension was transferred to the top chamber. Medium with 2% FBS was added
to the lower chamber. The plate was incubated at 37°C, 5% C02 atmosphere for 22 h.
Non-migrated cells in the upper chamber were removed with clean cotton swab, and
migrated cells on the bottom of the membrane were stained with Eosin and Gimsa
stain. The migrated cells were counted and invasion index was calculated by dividing
the percent of cells that migrated through the matrigel by the percent of cells that
moved through the pores of uncoated wells. The effect of secreted MMP-2 on
HUVEC cells invasion and migration was also performed using conditioned media in
the lower chambers of Boyden chamber wells.
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Table 3: Primer Sequences for MMPs and Integrins.
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Table 3
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Wound migration assay.

The wound migration assay was performed as described by Cheresh et al (164)
with slight modifications. HUVEC cells were grown in 35mm culture dishes to 80%
confluence. A wound was formed using a 200 III pipette tip to clear the cell
monolayer, and the boundary of the wound was marked. Cells were then washed three
times with PBS. The conditioned medium (CM) was applied in different combinations
with and without the MMP-2 blocking antibody. Mouse IgG (Sigma) was used as a
control. Cells were incubated for 18-20 h at 37°C, under a 5% C02 atmosphere. After
incubation, cells were fixed with absolute methanol, stained with diluted (1: 10)
Giemsa stain (Sigma Chemical Co., St. Louis MO), and photographed. Cell migration
was measured by counting the number of cells that migrated into the clear space using
an Olympus X-50 microscope at 100 X fitted with an ocular grid. The values
represented are the mean of four different random fields. The fold change was
determined by dividing the mean number of cells that moved from the wound edge in
the experimental cultures by those that moved from the wound edge in the control
cultures. HEK293 cells constitutively expressing PTTG were grown in 35 mm tissue
culture dishes to 80% confluence. A wound was formed with a 200 ul pipette tip. Cells
were washed thrice with IX PBS. Five ml of DMEM serum-free medium was added
to the dishes with or with MMP-2 blocking antibody (MMP2BA). After 24 hr of
incubation, cells were fixed with methanol, stained with 1: 10 diluted Giemsa stain,
and photographed as described earlier.
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Tubule formation assay in 3D matrigel matrix:

Forty-eight well plates were coated with 20 Ilg/ml of matrigel (GF-reduce BD
Bedford MA). HUVEC cells (2x10 3 cell/ml) were plated on the matrigel matrix with
conditioned medium (CM) with or with out MMP-2 blocking antibody for 24 h. After
4 h 100 III of matrigel-CM (matrigel + condition medium mixture 1:2 ratio) was
overlaid on cells. Cells were allowed to differentiate into tubule according to Lewis et
al

(165). After 3 days, tubule formations were assessed by fixing the cells with

methanol for 15 min, followed by rinsing with PBS. Three random fields of view in
three replicate wells for each test condition was visualized under high power Olympus
IX50 (X400). Color images were captured using Kodak DC290 digital camera linked
to a computer with Adobe Photoshop 7 software. Quantification of tubule formation
was carried out by counting the number of tubule branches and the total area covered
by tubules in each field of view using image analysis software Photoshop version 7. A
numerical value was assigned to each pattern according to the network of tubule
formation. A numerical value of 0-1 is given when the cells are well separated, 2-3
when cells begin to migrate and align to form tubes, and 4-5 when capillary tubes or
closed polygons begin to form.

Luciferase Assay:

A human MMP-2 promoter (1959 bp of the sequence upstream from the
transcription start site) cloned into luciferase reporter construct (pGL-MMP2) was
obtained from Dr. Etty Beneveniste, University of Alabama at Birmingham, AL
(Figure 18) (166).

Five hundred ng of the MMP-2 promoter construct or pGL2
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construct was co-transfected with 500 ng pcDNA-PTTG and 100 ng of the renilla
construct into 3 x 106 HEK293 cells using Transfectin (Bio-Rad). After transfection,
cells were allowed to recover for 18 h and then cultured in 10% FCS/DMEM for 24 h.
Cells were washed in PBS and lysed with 500 ).11 of IX lysis buffer (Promega);
luciferase activity was then determined in triplicate as described by the manufacturer.
The luciferase activity of each sample was normalized to renilla activity. The fold
change in luciferase activity was calculated by dividing the relative luciferase activity
ofPTTG-pGL-MMP2 promoter activity by PTTG-pGL luciferase relative activity.

Statistical Analysis:

Statistical comparison of data sets was carried out by the Student's t test
(single comparison) or by one-way ANOV A (multiple comparison) when data sets
complied with the condition of normality and equal variance. Under other conditions,
comparisons were carried out by nonparametric analysis using the Mann-Whitney
rank-sum test (single comparisons) or the Kruskal-Wallis one-way ANOV A on ranks
(multiple comparisons). The Bonferroni methods (parametric test) or the Dunett
methods (nonparametric test) were used to identify data sets that differed from the
control data in multiple comparisons. Probability of p <0.05 determined from the twosided test were considered significant. The statistical analysis was carried out by using
SPSS 10.0 software.
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Figure 18: Key regulatory elements in 1959 bp upstream of transcription start site of
human MMP-2 promoter sequence.
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Figure 18
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RESULTS
PTTG increases the expression and activity of MMP-2 in-vitro

Gelatinase A (MMP-2) was reported to correlate with invasive and metastatic
behavior of malignant tumors. Induction of MMP-2 protein had been implicated in
various diseases including tumor progression and metastases. We therefore measured
the expression and secretion of MMP-2 in HEK293 cells transiently transfected with
pcDNA3.1 and pcDNA3.1-PTTG·cDNA using The GE array for human extracellular
matrix and adhesion molecules and ELISA. As shown in (Figure 19 A and B), MMP2 expression was

~8

fold increased in the cells transfected with pcDNA-PTTG as

compared to cell transfected with pcDNA vector alone. Also, there was

~5

fold

increases in the MMP-2 secretion in pcDNA-PTTG transfected cells as compared to
pcDNA transfected cells. As shown in (Figure 19 C and D), MMP-2 mRNA levels of
MMP-2 protein in pcDNA3.1-PTTG transfected cells were increased by 22 fold

(p<O.05) compared to HEK293 cells transfected with vector-alone. Co-transfection of
HEK293 cells with pGL-MMP-2-Luc reporter gene and with pcDNA-PTTG resulted
in luciferase activity increased by 13 fold (p<O.05) relative to control pGL2 vector
(Figure 20). Measurement of the functional activity ofMMP-2 by zymography (Figure
21) and fluorescent collagenase substrate degradation revealed more than two-fold
increased in MMP-2 activation in cells transfected with PTTG cDNA compared to
cells transfected with vector alone (Figure 22). These data suggest that PTTG
increases MMP-2 expression as well as its activity, both of which may be required for
the tumor angiogenesis and invasive phenotype to degrade ECM to pave the way for
metastases.
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Figure 19: A: Selected data from GE Array for human extracellular matrix and
adhesion molecules are increased by more than two fold in HEK293 cells transfected
with pcDNA-PTTG vs pcDNA3.1. B: Measurement of MMP-2 and MMP-9 in
conditioned medium using ELISA, MMP-2 was approximately increased by 5-fold in
HEK293 cells transfected with pcDNA-PTTG compared to pcDNA transfected cells.
C: Semi quantitative RT-PCR for MMP-2 and GAPDH. D: Graphical representation
of the data shown in MMP-2 expression was increased by -22 fold in HEK293 cells
transfected with pcDNA-PTTG

compared to pcDNA3.1 transfected cells. (**

p<0.05).
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Figure 19 A and B
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Figure 20: MMP-2 promoter activation. MMP-2 promoter activity was increased by
~ 13

fold in cells transfected with pcDNA-PTTG as compared to pcDNA transfected

cells. Error bars represent mean ± SEM (n = 3). (** p<0.05)
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Figure 20
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Figure 21: A: Gelatin zymography. Activity of MMP-2 was increased in conditioned
medium from HEK293 cells transfected with pcDNA-PTTG

compared to cells

transfected with pcDNA plasmid. B: Densometric analysis of zymography showing
increase in inactive and active forms of MMP-2 in conditioned medium from HEK293
transfected with pcDNA-PTTG and pcDNA transfected cells.
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Figure 21

Zymography
pcDNA

---,

Inactive MMP-2

Active MMP-2

PTTG

C_",".MC~~"

•

Y"

_

'(

:,.:;..?~ ;'j~ ...

•

~~,;,

4.--------------------------------------,

"
:;'"
<3

2

31
o
u.

\.

~

Ill.

~

Inactive-MMP2

)

g
~

\.

~

Actlve-MMP-2

110

)

Figure 22: Direct Quenching (DQ) Fluorescein conjugate collagenease analysis.
Activity of collagenase was approximately 2.5 fold higher in conditioned medium
from HEK293 cells transfected with pcDNA-PTTG as compared to cells transfected
with pcDNA plasmid. Addition of MMP-2 blocking antibody (MMP2BA) completely
blocks the collagenase activity. Data represent the mean ± SEM of experiments
performed in triplicate. (* pO.OS)
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Figure 22
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MMP2BA

PTTG increases invasion and migration in-vitro.

To determine the role of PTTG on invasion and migration through MMP-2, we
used stably transfected HEK293 cells seeded on Boyden chamber wells. HEK293
stably transfected with PTTG cDNA cells showed higher invasive index compared to
HEK293 stably transfected with vector alone (Figure 23). We also observed a
complete inhibition of invasion and migration of cells in medium containing MMP-2
(2~g/ml)

blocking antibody (MMP2-Ab) as compare to conditioned medium from

pcDNA-PTTG transfected cells, and no effect on invasion with the addition of mouse
IgG (2~g/ml) as control.

Similar results were obtained using HUVEC cells. Increased invasion and
migration was observed in the conditioned medium from HEK293 transfected with
PTTG cDNA as compared to conditioned medium from vector transfected cells.
Complete inhibition of migration and invasion was observed when MMP-2

(2~g/ml)

blocking antibody was used as compared to control or without antibody.

PTTG increases the migration of HUVEC Cells in-vitro.

A wound migration assay was performed in 35mm culture plates seeded with
HUVEC, and migration was quantified by counting the number of cells that migrated
into the non-wounded area using a microscope eyepiece marked
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Figure 23: PTTG increased the invasion of HUVEC and HEK293 stably transfected
cells. A Matrigel coated Boyden invasion chamber assay was performed to evaluated
the invasion of HUVEC and HEK293 stably transfected cells.
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Figure 23
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grid (1 mm2 ). HUVEC cultures were incubated for 48 h in conditioned media from
HEK293 cells transfected with pcDNA3.l or pcDNA-PTTG. There was a 95%
increase in cell migration into non-wound area when conditioned medium from
pcDNA3 .1-PTTG compared to medium from cells transfected with vector alone
(Figure 24). Specific MMP-2 blocking antibody suppressed migration by 87% into the
wounded area as compared to conditioned medium from pcDNA-PTTG, but there was
no effect on migration with rabbit/mouse IgG (data not shown).

PTTG increases tubule formation and growth in 3D matrigel matrix.

MMP-2 plays an important role in the proteolysis of ECM that allows
endothelial cells to migrate toward the angiogenic stimuli and form the blood vessels
that nurture tumor development. A HUVEC cell in three dimensional matrigel matrix
was mixed with conditioned medium from HEK293 transfected cells with pcDNA or
pcDNA-PTTG with or without MMP-2 blocking antibody. As shown in (Figure 25)
the tubule formation was enhanced in CM from pcDNA3.1-PTTG as compared to
vector alone. Treatment with MMP-2 blocking antibody completely abolished tubule
formation, suggesting an important role ofMMP-2 in angiogenesis. On the other hand,
when stable transfected HEK293 cells were grown on a matrigel matrix, cells which
were transfected with vector alone did not grow and remained spherical after 48 hrs
(Figure 26), whereas cells transfected with pcDNA-PTTG spread out and started
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Figure 24: Conditioned medium from PTTG transfected HEK293 cells increased the
migration of HUVE cells as compared to pcDNA transfected HEK293 cells.
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Figure 24
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Figure 25: Tubule formation assay: HUVEC cells were grown in matrigel matrix
mixed with conditioned medium collected from pcDNA-PTTG or pcDNA3.l
transfected HEK293 cells, and pcDNA-PTTG + MMP2 blocking antibody
(MMP2BA).
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Figure 25
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growing within 24 h. On the other hand, inclusion of MMP-2 blocking antibodies,
completely blocked the growth of these cells. These data suggest a role for MMP-2 in
proliferation and growth of cells.

PTTG increases the expression of alpha-5, alpha-V, beta-l and beta-3 integrins.

Integrins are a diverse family of glycoproteins that form hetrodimer receptors for
ECM molecules. The family can form at least 25 distinct pairs of 18 a-subunit and 8
~-subunits,

with each other specific for a unique set of ligands. Integrin

aV~3

binds a

wide range of ECM molecules including fibronectin, fibrogen, vitronectin and MMP,
and proteolyse collagen and laminin, whereas

a5~1

selectively binds to fibronectin

(167). Numerous studies have documented marked differences in surface expression
and disregulation of integrins in malignant tumors compared with pre-neoplastic
tumor of the same types (168). Integrin a5~3 is strongly expressed at the invasive front
of malignant melanoma cells and angiogenic blood vessels (169), and expression of av
and

~3

integrin increases the metastatic potential of various tumor cell lines (170). As

shown in (hgurc 27) the mRNA levels of alpha-5, alpha-V, beta-l and beta-3 are
significantly increased in HEK293 cells transfected with pcDNA-PTTG as compared
to pcDNA3.l

PTTG increases the expression and secretion of MMP-2 in-vivo.

Analysis of MMP-2 expression, secretion, and activity in tumors excised from
nude mice overexpressing PTTG confirmed the higher expression of MMP-2 mRNA
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(Figure 28) measured by RT/PCR, activity measured by zymography, and DQ
fluorescent substrate activity.

3.2.5

DISSCUSSION:

Pituitary tumor transforming gene (PTTG) is a potent oncogene expressed at
high levels in almost all malignant tumor analyzed to date. Its oncogeneic potential
was demonstrated by its over-expression in mouse fibroblast NIH3T3 and HEK293
cells, which showed increased proliferation, colony formation on soft agar and tumor
formation in nude mice (24,27,72). Expression ofPTTG has been reported to correlate
with highly aggressive and metastastic tumors (33,71), and to regulate the expression
of many growth and angiogenic factors such as bFGF, VEGF and IL-8 (72). However,
the mechanism by which this aggressive behavior is regulated remains unclear.
Metalloproteinases are central to the ability of cancer cells by regulating the
extracellular matrix (ECM) around them. They degrade the matrix, and make way for
the tumor cells to migrate and metastasize to distance sites. It is well recognized that
MMPs are also involved in the expression and activation of various chemokines,
growth factors and their receptors (171). Multiple MMPs are involved in the
degradation of the surrounding matrix, but MMP-2 has been at the forefront in tumor
invasion, angiogenesis, and formation of metastases. Tumor and stromal cells express
high levels of MMP-2, which allows the cells to invade and metastasize. However
cellular mechanism by which MMP-2 is regulated is not fully understanded. To
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Figure 26: Three dimensional growth assay. HEK293 cells were grown in matrigel
with or without MMP-2 blocking antibody mixed with conditioned media from
pcDNA-PTTG or pcDNA3.l transfected HEK293 cells.

123

Figure 26

3D Cell Growth Assay
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Figure 27: Semi quantitative RT-PCR for Integrins and GAPDH. Expression of beta1, beta-3, alpha-5, and alpha-V was increased in HEK293 transfected with pcDNAPTTG cells as compared to pcDNA3.1 transfected cells. Densometric analysis of gel
showing the expression of integrins in HEK293 cells transfected with pcDNA-PTTG
or pcDNA3.1.
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Figure 27
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Figure 28: Expression of PTTG and MMP-2 in tumor excised from nude mice. A:
Semi-quantitative RT-PCR. B: Zymography. C. In-situ fluorescence collagenase
activity.
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Figure 28

RT-PCR on Tumor Tissues and Normal Tissues

---- T1

A

T2

T3

H

--

Lu

-

-----

PTTG
MMP-2

GAPDH

Zymography on Tissue lysate

B

MMP-2 (in-a.tive)
MMP-2 (a.tive)

- ---

DQ Fluorescein Conjugate Collagenase Assay

C

Organ Tissue

Tumor Tissue

128

investigate the interrelation between PTTG and MMP-2 in anglOgemc and
InVaSIVeness of tumor cells, we selected HEK293 cells. Stable overexpression of
PTTG in HEK239 increased the expression and secretion of MMP-2, which in tum
increased invasion, migration, and tubule formation of HUVEC cells treated with
conditioned medium. Treatment with specific MMP-2 blocking antibody inhibited
migration, invasion, and tubule formation of HUVEC cells, suggesting that MMP-2 is
crucial in migration, invasion, and angiogenesis. Many studies have implicated MMP2 in tumor angiogenesis and metastases (172-174). Itoh et al reported a significant
reduction in angiogenic activity and subsequent tumor progression in MMP-2
deficient mice (141). Others have shown that MMP-2 is required for tumor
angiogenesis and metastases (158,175). As cancer cells become metastatic and
endothelial become angiogenic, they develop altered affinity for their extracellular
matrix. Some of these changes are mediated by alteration in the expression of cellsurface molecules known as integrins. Integrins are involved in regulating the
activities of proteolytic enzymes that degrade the basement membrane, the initial
barrier to surrounding tissue, by directly mediating adhesion to ECM, and also by
regulating intracellular signaling pathways that control cytoskeleton organization. As
PTTG is involved in regulation of cell cytoskeleton (45) these changes could occur
through the expression of different integrins on the cell surface, as we have showed
that integrin av, as,

~l

and

~3

expression is measured by overexpression of PTTG in

HEK293 cells. Integrin av and

~l

have been impicated in the regulation of

metalloproteinases MMP-2 and MTI-MMP with whom it forms a complex in highly
invasive phenotypes of metastatic tumors (176,177). In previous studies, we (72)

129

showed that PTTG stimulates the expression of bFGF, VEGF and IL-8, which may
induce the expression of MMP-2 (178). Overexpression of PTTG in HEK293 cells
may have autocrine effects on the expression of MMP-2 initiated by growth factors.
However, the studies done by Hyuga et al (179) showed autocrine factors were not
responsible for the upregulation of MMP-2 in highly metastastic cell line. Tumors
excised from nude mice also displayed higher expression and collagenase activity
when compared to normal organs from the same animals, except in the liver and
kidney which express MMP-2 for their normal function (180,181).

In summary, our results provide evidence that PTTG contributes to cell
migration, invasion and angiogenesis by induced of MMP-2 expression and secretion.
Further, we showed that tumors from nude mice have high expression and secretion of
MMP-2 which contributed to high gelatinolytic activity. However, due to the
expression of other contributing growth factors we are unable to show autocrine effect
on MMP-2 expression and secretion. Further studies are needed to separate the
autocrine effect of growth factors on MMP-2 expression.
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Chapter IV

Regulation of Matrix Metalloproteinase-2 (MMP-2) in human tumor cells lacking
Pituitary Tumor Transforming Gene (PTTG -/-).

INTRODUCTION

Tumorigenesis is a multistep process. Abnormal gene expression is associated
with several characteristics that differentiate tumor cells from normal cells, including
alterations in cell differentiation, invasion, migration, metastasis, angiogenesis and
apoptosis. Over-expression of human pituitary tumor transforming gene (PTTG) in
mouse fibroblast NIH3T3 cells and human embryonic kidney (HEK239) cells results
in increased cell proliferation, induction of the cell foci formation and promotion of
tumor formation in nude mice (24,26,27,72). These finding suggest that PTTG is a
potent human oncogene. Data from our laboratory and others suggested that PTTG
may act through bFGF, VEGF, IL-8 and MMP-2 to achieve cellular transformation
leading to tumorigenesis.

Local invasive growth is a key event of primary malignant tumors. A
correlation between the expression levels of PTTG and invasiveness and degree of
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malignancy in pituitary, colorectal and thyroid tumor has been demonstrated
(33,35,36). However, specific mechanisms facilitating the invasive behavior of cells
expressing PTTG remains unclear. Interaction between cancer cells and surrounding
normal cells, involving extra-cellular matrix (ECM) are thought to be the key to tumor
cell invasion (182,183). To invade and metastasize into the surrounding normal
tissues, tumor cells must degrade multiple elements of the ECM, including fibronectin,
laminin, and type IV collagen (183). Several metalloproteinases (MMPs) are required
for the degradation of the ECM and these are classified according to their substrate
specificity. Gelatinases (MMP-2 and MMP-9) are the most common MMPs found in
tumors, and elevated levels of these enzyme have been reported in various cancers
(183). MMP-2 is also known to be involved in tumor angiogenesis through
degradation of extracellular matrix which can result in tumor cell as well as
endothelial cell migration due to loss of cell-matrix and cell-cell contacts (145). MMP2 is also capable of releasing growth factors from ECM, cleaving growth factor
receptors and activating growth factors excreted as pre-pro-enzymes, such as
transforming growth factors (TGFu, TGFP), macrophage-colony stimulating factor
(M-CSF), insulin like growth factor (IGF) and fibroblast growth factor receptor
(FGFR) (146-148).

As discussed in the chapter III, PTTG regulates the expression and secretion of
MMP-2 in HEK293 cells. Recent data from our laboratory Kakar et al; (184) and
others (70,86-88) showed that attenuating PTTG expression using siRNA, antisense
oligos or adenovirus mediated transfer of siRNA against PTTG, inhibit tumor growth
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of ovarian, lung and hepatoma cancer cell lines in vitro and in vivo. None of these
studies examined the metastastic or invasive properties of these tumors. The aim of
this study is to utilize cancer cells genetically lacking PTTG gene to determine its
effect on tumor invasiveness and determine the role ofMMP-2 in such regulation. We
hypothesized that deletion of PTTG will reverses the invasive phenotype by
decreasing MMP-2 expression and secretion. To support our hypothesis we used
human colorectal tumor cell line HCT116 lacking PTTG (PTTG -1-), and wild type
HCT116 (PTTG +1+) cells as control. These cell lines were a generous gift from Dr.
Vogelstein (John Hopkins Oncology Center and Howard Hughes Medical Institute.
Baltimore. Maryland) (89).

4.2

MATERIAL AND METHODS:

Cell cultures

Human colorectal cancer cells lines were obtained from Dr. Bret Vogelstein
(The John Hopkins Oncology Center and Howard Hughes Medical Institute. Baltimore
Maryland) (89) and propagated as described elsewhere (185,186).

Western Blot:

Cells growing in log phase were lysed in chilled lysis buffer [50 mM Tris-HCl
(pH 7.5),150 mM NaCl, 1% NP-40, 1 mM Na3V04, and 1 mM NaF] supplemented
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with Complete Mini Protease Inhibitor tablets (Roche Molecular Biochemicals,
Indianapolis, IN). Equal amounts of protein extracts (40 ug) were resolved on 12%
SDS-PAGE gel, and transferred to a nitrocellulose membrane (Amersham,
Piscataway, NJ). Blots were probed with PTTG antiserum at a dilution of 1: 1,500 as
described previously (124). Immunoreactive proteins were visualized using the
Enhanced Chemiluminescent Detection System (Amersham) according to the
instructions provided by the supplier.

Reverse Transcription Polymerase Chain Reaction (RT -PCR):

Total RNA from cells was purified using Trizol reagent (Invitrogen, Carlsbad,
CA) following the manufacturer's instructions. The RNA pellets were resuspended in
RNase-free water, and contaminating DNA was removed from the preparations with
DNase!. The yield of total RNA was measured using a spectrophotometer, and the
quality was assessed by electrophoresis through a 1% agarose gel. First strand cDNA
was synthesized using the iScript™ cDNA synthesis kit (BioRad, Hercules, CA). PCR
primers were designed, based on the human PTTG, MMP-2 and GAPDH cDNA
sequences. The PCR conditions for each gene are listed in Table 1 & 2. GAPDH
amplification was used as an internal control. Ten III from a total of 50111 PCR reaction
mix was applied to a 2% agarose gel. After electrophoresis the gel was stained with
ethidium bromide to visualize PCR products. The densitometric values for the PCRamplified products were quantified using BioRad software and normalized against the
GAPDH values.
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Zymography:
Secretion and activity of MMP-2 in conditioned medium collected from cells was used
to perform gelatin zymography analysis as described by Heussen et al (159,160).
Briefly conditioned medium was collected and one ml of medium was lyophilized and
reconstituted to 100 I.d with water. Protein was determined by Bradford method (161)
and 20

~g

of protein from each sample was loaded on polyacrlyamide gel containing

0.1 % gelatin Sigma Co. (St. Louis, MO). Electrophoresis was performed under nonreducing conditions at 20 rnA for 3 hr at room temperature. The gel was washed twice
for 30 min each in 2.5% Triton X-IOO to remove SDS, incubated in substrate buffer
(50 mM Tris-HCI, 5mM CaCh, 0.01 % NaN3 , pH 7.6) for 24 h at 37°C. The gel was
stained with 0.5% Coomassie brilliant blue G-250 (Pierce Rockford, IL) for 30 min at
room temperature, and de stained in the de staining buffer (30% ethanol, 10% acetic
acid, deionized water). The presence of metalloproteinases (MMP-2) was indicated by
an unstained proteolytic zone of substrate. The gel was scanned using NIH image
software, and data are presented as fold change relative to control i.e, HCTl16 WTconditioned medium.

Detection of collagenase activity in conditioned medium and tissue sections.

Collagenase activity in conditioned medium (CM)

Twenty microliters of collagen fluorescent substrate reconstituted in PBS was
mixed with 80

~l

of reaction buffer (0.5 M Tris-HCL, 1.5 M NaCI, 50 mM CaCh, 2
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mM NaN3, pH 7.6) and added to the fluorescent reader plate. Twenty III of
conditioned medium was added to each well. Clostridium collagenase, serially ten fold
serially diluted used as a positive control and 100 III of reaction buffer was a negative
control. The plate was incubated at room temperature for 1 h. After incubation, the
fluorescent intensity of the digested product from DQ collagen was measured by
excitation at 495 nm and emission at 515 nm in the fluorescent microplate reader. The
fold change in activity was calculated by dividing the mean of fluorescence values of
conditioned media collected from HCTl16 WT by the mean value of fluorescence of
conditioned media collected from HCTl16 Null (PTTG-I-) cells.

Luciferase Assay:

A human MMP-2 promoter (1959 bp upstream from transcription start site)
luciferase reporter construct (pGL-MMP2) was obtained from by Dr. Etty
Beneveniste, University of Alabama at Birmingham, AL (166). Five hundred ng of
the MMP-2 promoter construct or pGL2 was co-transfected with 100 ng of a renilla
construct into 3 x 106 HCT116 WT and HCT116 Null (PTTG-I-) cells using
Transfectin (Bio-Rad). After transfection, cells were allowed to recover for 18 hand
then cultured in 10% FCS/DMEM for 24 h. Cells were washed in PBS and lysed with
500 III of IX lysis buffer (Promega). Luciferase activity was determined in triplicate
as described by manufacturer. The luciferase activity of each sample was normalized
to renilla activity to determine the relative luciferase activity (RLA). The fold change
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in RLA was calculated by dividing the relative luciferase activity of HCTl16 WTpGL-MMP2 promoter activity by HCTl16 Null-pGL-MMP-2Iuciferase activity.

Migration Assay:

HCT116 WT and HCT116 Null (PTTG-/-) cells were cultured in McCoy's
medium containing 100 mllL FBS and 10 gIL penicillin-streptomycin in a 50 mllL
CO2 incubator at 3TC. Assessment of HCTl16 migration was performed as recently
described (187) with minor modifications. HCT116 cells were dispersed into
homogeneous single cell suspensions after trypsinization. These cells were extensively
washed with McCoy medium containing 1 giL fatty acid-free BSA and resuspended in
the same medium. HCTl16 cells (105) were dispersed onto the upper chamber of
transwell compartment with an 8

~m

pore size filter (QCM Cell Migration Assay,

Chemicon. USA). The cells were allowed to adhere for 1 h at 3TC. The medium in
the lower chamber was removed and replaced by growth medium alone. Migration
was allowed to proceed for 24 h at 3TC. The remaining cells attached to the upper
surface of the filters were carefully removed with cotton swabs. Migrated cells were
stained with crystal violet and examined by light microscopy and photographed. The
number of migrated cells was quntitated by dissolving stained cells in 10% acetic acid
and transfering a 100

~l

of dye/solute mixture to a 96 well plate for colorimetric

reading at at 560 nm. Data were expressed as mean ± SD of the three independent
experiments.
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Invasion Assay:

HCT116 WT and HCT116 Null (PTTG-I-) cells were cultured in McCoy
medium containing 100 mllL FBS and 10 giL penicillin-streptomycin in a 50 mIlL
CO2 incubator at 3TC. Assessment of HCT116 migration was performed as recently
described above (187-189).

Percent Invasion:
Percent invasion was calculated by dividing mean of cell invaded through
matrigel insert membrane by mean of cells migrating through control insert membrane
and multiplied by 100.

Statistical Analysis:
Statistical comparison of data sets was carried out by the Student's t test, and
by one-way ANOV A for multiple sets using SPSS v 10.

4.3

RESULTS:

Loss of PTTG expression in HCT116 (PTTG -1-) correlates with the expression
ofMMP-2.

Over-expression of MMP-2 correlates to an invasive phenotype in several
cancer types and is often predictive of poor survival (140). MMP-2 null mice display
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lower lung colonization following intravenous administration of cancer cells and
reduced tumor angiogenesis resulting in reduced tumor growth (141). PTTG regulates
the MMP-2 expression in the HEK293 cell line, which increases the invasive behavior
of these cells. To determine the functional effect of PTTG on MMP-2 regulation,
colorectal cancer cell lines lacking PTTG gene HCT116 (PTTG -1-) and its control
HCTl16 wild type (PTTG +1+) were used.

To test the validity of HCT116 (PTTG +1+ and -1-) cell lines as a model
system, western blot analysis for PTTG was carried out. As shown in (Figure 29),
expression of PTTG protein in HCTl116 (PTTG -1-) was undetectable, whereas
HCT116 (PTTG +1+) cells showed high levels of PTTG protein. Further, to
demonstrate an effect of PTTG on MMP-2 gene transcription, MMP-2 promoter
activity was measured in HCT116 (PTTG +1+) and HCTl16 (PTTG -1-) cell lines.
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Figure 29: Western blot analysis of HCT116 wild type and HCT116 (PTTG -1-) cells
showing PTTG and GAPDH protein expression.
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Figure 29

Western Blot
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A 1659 bp DNA fragment containing human MMP-2 gene promoter cloned into the
pGL3 (Promega) vector was co-transfected with renilla vector. After 24 h growth
medium was changed to serum-free medium. 24 h after the change in medium, the
cells were lysed and assayed for luciferase activity as described previously (80). As
shown in (Figure 30) MMP-2 promoter activation was increased by

~8

fold higher

(p<0.05) in HCT116 (PTTG +1+) compared to the HCTl16 (PTTG -1-) cell line.
Similar results were obtained by the semi-quantitative reverse transcription (RT-PCR)
analysis of messenger RNA of PTTG and MMP-2. As shown in (Figure 3]), the level
of PTTG mRNA was higher in wild type HCT116 cells but undetectable in HCT116
(PTTG -1-) cell line. Similarly, the mRNA level of MMP-2 was higher in HCT116
(PTTG +1+) compared to HCTl16 (PTTG -1-) cells. As described in chapter III, overexpression of PTTG increases the expression of MMP-2 in HEK293 cells. To confirm
our results of MMP-2 we measured MMP-2 secretion and activity in HCT116 cells.
DQ-collagenase and zymography assays. As shown in (Figure 32), there was
substantially less secretion of MMP-2 by the HCT116 (PTTG -1-) cell lines as
compared to HCT116 (PTTG +1+) cell line. Furthermore, the collagenolytic activity of
MMP-2 was reduced by 30% in medium from HCT116 (PTTG -1-) as compared to
HCT116 (PTTG +1+) cells.
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Figure 30: Luciferase assay ofMMP-2 promoter transfected in HCTl16 wild type and
HCT116 (PTTG -1-) cells.

** p<0.005
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Figure 30
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Figure 31: Semi-quantitative RT-PCR for PTTG, MMP-2 and GAPDH in HCT116
(PTTG +1+) and HCT116 (PTTG -1-) cells.
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Figure 31

RT-PCR
+1+

-1-

PTTG

180
:I:
a 160

L

MMP-2

~
S

140

!==

100

.

60

•E
IS

z

.t!
L

120
80
40
20

~~

0

GAPDH

HCT-WT

p<O.OO5

146

HCT-Null

Figure 32: Zymography and Collagenase assay of conditioned media collected from
HCTl16 wild type (PTTG +1+) and HCTl16 (PTTG -1-) cells
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Decrease in MMP-2 expression reduces the invasive phenotype of HCT116
(PTTG -1-) cell line.

A relationship between PTTG expression and metastasis has been reported
(33,68) in limited studies in colorectal and pituitary adenocarcinomas. As mentioned
earlier, MMP-2 is thought to have a prominent role in tumor cell invasion and is
increased by PTTG. We next tested ifPTTG stimulated the expression ofMMP-2, the
invasive behavior ofHCTl16 (PTTG +1+) and HCTl16 (PTTG -1-) cells. The Boyden
chamber matrigel invasion assay were used to measure the invasive index of both cell
lines. As shown in (Figure 33 A) there was a significant decrease in both invasion and
migration of HCT116 (PTTG -1-) cells as compared to HCT116 wild type. There was
also a

~39

% reduction in invasion of HCT116 (PTTG -1-) compared to HCT116

(PTTG +1+) (Figure 33 B). These results suggest that PTTG modulates the expression
ofMMP-2 in mediating its tumorigenic function.

4.4

DISCUSSION

In this chapter it is shown that PTTG plays an important role in regulating the
expression of MMP-2. Deletion of the PTTG gene from the HCT116 cell line is
associated with a reduction of MMP-2 expression
this cancer cell line. These finding are consistent
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an~

decreased invasive capacity of

Figure 33: Invasion and migration assay using HCTl16 wild type and HCTl16 (PTTG

-1-) cells. Percent invasion was calculated as mentioned in material and methods.
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Figure 33
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with the previous results from our group using siRNA against PTTG (184) and others
using PTTG full length anti-sense mRNA (88), or oligonucleotides against PTTG
mRNA (190), reduced colony formation on soft agar, and suppression of tumor
development in nude mice. PTTG is over-expressed in most types of cancer and plays
an

important

role

m

tumor

.

.

angIOgenesls,

metastasis

and

growth

(24,25,33,71,72,124,151). Over-expression of PTTG has been shown to induce
cellular transformation and to promote tumor development in nude mice (72). MMP-2
plays an important role in local invasion, angiogenesis and growth. A correlation
between the levels of expression of PTTG with increased tumor invasiveness and
degree of malignancy in pituitary and colorectal tumors have been demonstrated
(33,68). Melmed et al (85) showed that when the PTTG gene is ablated animals
exhibited impaired proliferation of pancreatic p-cells and developed type I diabetes
during late adulthood, suggesting the importance of PTTG in p-cell proliferation.
These results are in agreement with Perez et al (191) showing that MMP-2 is required
for pancreatic islet cell formation (191), and other studies of diabetes and p-cell
dysfunction where MMP-2 expression is impaired (192). These results suggest that
PTTG null animals have impaired pancreatic p-cell proliferation and development of
diabetes may be due to impaired MMP-2 expression.

MMP-2 activity was still observed in PTTG -/- cells line, suggesting that
PTTG is not the only factor which can lead to the regulation ofMMP-2 (193-196). On"
the other hand, PTTG ablation in HCT116 may change the phenotypic characteristic
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of the cells during positive selection, and other genetic or biochemical alterations
which might have occurred that lead to cell survival cells without PTTG.

In conclusion, PTTG expression correlates with the expression of MMP-2 in
HCT116 cell lines. Depletion of PTTG from HCT116 (PTTG -1-) decreased the
transcription of MMP-2, which in-tum decreased the expression, secretion, and
activity of MMP-2. These together effect cell migration and invasion characteristics of
HCTl16 cells. The data suggest that PTTG is a potent oncogene that may act through
bFGF, VEGF, IL-8 and MMP-2 to induce transformation, cell proliferation,
angiogenesis, invasion, and metastasis. MMP-2 is crucial in all steps of tumorigenesis;
blocking MMP-2 activity can inhibit the multistep process of tumorigenesis.
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Chapter V

CONCLUSIONS AND DISCUSSION

Pituitary tumor transforming gene (PTTG) is a relatively recently isolated
proto-oncogene that has been identified as a mammalian securin protein implicated in
chromatid separation during cell division (45). Expression of PTTG is cell cyc1edependent both at the protein and mRNA levels (45,47,66). By virtue of mammalian
securing activities, PTTG over-expression inhibits of chromatid separation which may
lead to genetic instability, aneuploidy and thereby tumorigenesis (45) The oncogeneic
function of PTTG was established by over-expressing the protein in mouse fibroblast
cell line (NIH3T3) and assessing its ability to induce cellular transformation and
tumor formation in the nude mice (24,27). Expression of PTTG in NIH3T3 cells
increaseds bFGF and VEGF expression thereby

leading to tumorigenesis and

angiogenesis in vitro and in vivo (35,90). bFGF and VEGF are major activating factors
in mitogenesis and angiogenesis (90,91). Thus, PTTG may playa role in tumor
progression and angiogenesis.
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There are numerous instances in which overexpreSSlOn of oncogenes induce
transformation rodent cell lines, but have failed to transform the same cells type from
humans (96). It is now widely accepted that human tumorigenesis is a multistep
process and requires activation of more than one oncogene (197).

The goal of this study was three fold. First, to determine whether PTTG can
induce the transformation of normal human cells; second, to determine if PTTG is
sufficient to induce transformation, and third, to characterize the changes in secretion
and expression of the key angiogenic and metastatic factors bFGF, VEGF, IL-8, and
MMP-2. To address our hypothesis and to investigate the role of PTTG in
tumorigenesis, I used the human embryonic kidney cell line (HEK293). This cell line
has been transformed by human adenovirus type 5 to prevent senescence (112) and
HEK293 cells displays moderate tumorigenic potential (113).

Our data demonstrate that overexpression of PTTG in HEK293 cells increases
cell proliferation and induces cellular transformation in vitro as demonstrated by
colony formation on soft agar and tumor growth in nude mice. By contrast, cells
transfected with pcDNA 3.1 vector as control did not cause colonies of tumor cells to
grow in soft agar nor did they promote the development of tumors when implanted in
nude mice. These results are in agreement with the previous studies (24,27) that
demonstrated an effect of PTTG to transform NIH3T3 mouse fibroblast cells. Second,
demonstrated that PTTG alone is sufficient to induce transformation of primary human
cells without the cooperation of other oncogenes to achieve its tumorigenic function.
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Often, a single oncogene is not sufficient for the induction of transformation, but
requires co-operation of other oncogene(s) to induce tumorigenesis in primary human
cells (96,116,118,119,134,198). However, HEK293 cells are transformed by
adenovirus type 5, have achieved the limitless growth advantage over their normal
counterpart. Our data suggest that PTTG is sufficient by itself to initiate the
transformation of HEK293 cell line, and we have demonstrated that PTTG overexpression in HEK293 cells accelerates their tumorigenic capacity compared to nontransfected or vector transfected HEK293 cells. PTTG contains two PXXP motif in the
proline rich region near C-terminal identified as SH3-binding site (27); these sites are
critical as mutation of these regions causes the loss of transforming and transactivating
activity of PTTG. Our data clearly demonstrate that the mutation of these sites
abrogates the tumorigenic function of PTTG in human cells. The question arises that
the loss of tumorigenic function of PTTG may be due to loss of expression due to
mutation, but western blot analysis of a stable clone demonstrated constitutive
expression of mutated PTTG protein in HEK293 cells. This suggests that the loss of
tumorigenic function of mutated PTTG clones was not due to loss of expression but
loss of its ability to induce cellular transformation. Consistent with the results of other
investigators using rodent cells (27,55), we confirmed the importance of the Cterminal proline-rich motif in mediating the oncogenic function of PTTG.

The mechanism of tumorigenesis by which PTTG induces cell transformation
remains unclear. Apart from the role its cell division, PTTG regulates bFGF
expression (27). bFGF has previously been implicated in the growth and development
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of other tumors (75) and the growth of tumors depends mainly on adequate
vascularization (91).

VEGF and IL-8 have also been shown to increase tumor

vascularization and migration of endothelial cells (108,199,200). Consistent with the
hypothesis that PTTG may promote tumorigenesis by upregulation of angiogenic
factors; our data clearly show significant increases in the expression and secretion of
bFGF, VEGF and IL-8 when PTTG is over-express in HEK293 cells, suggesting, a
role of PTTG in angiogenesis and tumor promotion. This notion recently raised the
question that PTTG may form collaborate with other genes to activate the angiogenic
switch in tumor initiation and progression. McCabe et al (78) investigated several
angiogenic genes regulated by PTTG in primary thyroid cells. Result from eDNA
microarray analysis of angiogenic factors showed upregulation of several angiogenic
promoter genes, including inhibitor of DNA binding-3 (ID3), and down-regulation of
inhibitors of the angiogenesis gene thrombospondin-l (TSP-l), suggesting that PTTG
may play an important role in the angiogenesis.

For a tumor to grow successfully and metastasize, it requires a continuous
supply of nutrient and oxygen. Without angiogenesis tumors cannot grow larger than
few mm3 (91). One of the early steps in tumor angiogenesis is degradation of ECM
catalyzed by MMPs that enable endothelial cells to migrate and proliferate to form
new vessels (201,202) and to metastasize, by facilitating the movement of tumor cells
from primary site, to distant organs. Matrix metalloproteinases (MMPs) play a key
role in this processes by degrading the extracellular matrix and controlling the
biological activities of growth factors, chemokines and cytokines to favor tumor
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angiogenesis and metastasis (98). Our data clearly indicate that over-expression of
PTTG in HEK293 cells increases the expression and secretion of MMP-2. This
increase of MMP-2 activity is due to an increase in at both mRNA and protein levels
as demonstrated by MMP-2 promoter activity and zymography analysis. MMP-2
involved in tumor angiogenesis, mainly through it degradative capacity, and can result
in tumor cell and endothelial cell migration due to loss of cell-matrix contacts and
cell-cell contact (145,156,174). Our data indicates that the increase in expression and
secretion of MMP-2 by PTTG over-expression enhances the invasion and migration of
both HEK293 and endothelial cells. Increases in MMP-2 secretion also promote the
tubule formation of HUVEC cells in 3D collagen matrix that is analogous to
angiogenesis. By using a specific inhibitor that inhibits MMP-2 activity, we showed a
decrease in MMP-2 activity and loss of its ability for invasion, migration and tubule
formation of HUVEC, suggesting a specific role of MMP-2 in angiogenesis and cell
InVasIOn.

Tumors developed in nude mice show increased expression of MMP-2 mRNA
and MMP-2 activity, compared to other tissue from same animals. MMP-2 is secreted
as a latent pro-MMP-2 form, for the activation of MMP-2 it requires a active
interaction of another class of membrane bound metalloproteinase know as MT-1MMP and tissue inhibitor of metalloproteinases-2 (TIMP2) (139). A balance between
the concentration of MMP-2 and TIMP-2 is needed for the activation of MMP-2 at
cell surface (203). Our data clearly demonstrate an increase in the expression ofMTlMMP and decreased expression of TIMP-2 in the cells over-expressing PTTG
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compared to cells transfected with vector. These data indicate that PTTO not only
increases the expression of MMP-2 but also regulates the activity of MMP-2 by
altering the expression of MT-1-MMP and TIMP-2.

PTTO over-expreSSIOn has been reported in

varIOUS tumors, including

pituitary (35), thyroid (69,154), colon (33), ovary and breast (25). In thyroid, pituitary,
oesophageal and colorectal tumors, high PTTO expression correlates with tumor
invasiveness (27,33,71,154). Furthermore, PTTO has recently been identified as a key
metastatic "signature gene" with high expression in multiple tumors (36). It remains
unknown whether PTTO is essential for regulating angiogenesis and metastasis by
regulating MMP-2 and whether deletion of PTTO will reverse the cancer phenotype
by decreasing the expression and secretion of MMP-2. Data from our studies show
that deletion of PTTO from a human colorectal cancer line HCT116 (PTTO -1-)
decreased expression and secretion of MMP-2. This decrease was associated with
decreased potential of HCT116 (PTTO -1-) cells to invade through matrigel compared
to wild type HCT116 (PTTO +1+) cells. Consistent with the results of Kakar and
Malik (184) and Hassanain et al (unpublished data) and others (70,86,88) using siRNA
or oligonucleotides method to decrease the expression of PTTO in tumor cells resulted
in decrease cell proliferation, increase in apoptotic figures, decrease in number of
colonies formed on soft agar, and inhibition of tumor formation in nude mice.

In conclusion I demonstrated that PTTO is a potent oncogene, its overexpression in human cells can induce cellular transformation by increasing the cell
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proliferation, enhancing colony formation in soft agar in-vitro and, promote tumor
formation on injection human cells transfected with PTTG cDNA in nude mice. The
possible

mechanism by which PTTG induces

angiogenesis,

invasion and

tumorigenesis is by increasing the expression of growth factors such as bFGF, VEGF,
IL-8 and MMP-2. Depletion of PTTG from the HCTl16 cells appears to abrogate its
possible role in tumorigenesis by suppression of MMP-2 expression.
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